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Resistance to cephalosporins may lead to untreat-
able gonococcal infections. We describe the results 
of the sentinel surveillance of gonococcal infections 
and the evolution of the resistance of Neisseria gon-
orrhoeae to antibiotics in France from 2001 to 2012. 
We also analyse the factors associated with decreased 
susceptibility to third generation cephalosporins. In 
France, surveillance of gonococcal infections is con-
ducted through a network of voluntarily participating 
laboratories. Strains are sent to the national reference 
laboratory to determine the minimum inhibitory con-
centration (MIC) for six antibiotics. During the study 
period, the number of gonococcal infections increased 
steadily. The susceptibility of 8,649 strains was stud-
ied for this period. The proportion of strains with 
decreased susceptibility to cefixime (MIC>0.125 mg/L) 
quadrupled between 2011 (0.7%:10/1,521) and 2012 
(3.0%: 33/1,093; p<0.001). Between 2001 and 2012, 
only two of the 8,649 strains, both collected in 2010, 
had a MIC>0.125 mg/L for ceftriaxone. Decreased sus-
ceptibility to cephalosporins increased with older 
age and was more common in pharyngeal strains. 
Decreased susceptibility to cefixime may indicate that 
the national recommendation to use ceftriaxone as a 
first line treatment for cases of urethritis and cervici-
tis has not been fully implemented. Enhanced surveil-
lance of pharyngeal strains is strongly suggested. 
Introduction
Although gonorrhoea is a common sexually transmit-
ted infection (STI), normally responsible for uncompli-
cated genital infections, the disease can sometimes 
lead to severe complications (salpingitis, epididymo-
orchitis, septicaemia) [1,2]. It also increases the risk of 
transmission by human immunodeficiency virus (HIV) 
[2]. Because of its short incubation time (mainly 2 to 5 
days) [3] and characteristic symptoms in men, the inci-
dence of gonorrhoea can be used as a very sensitive 
indicator of the relaxation of safe sexual behaviours, 
and as an early warning signal for increased risk of HIV 
transmission [2].
Following acquired immunodeficiency syndrome (AIDS) 
prevention campaigns in the 1980s and at the begin-
ning of the 1990s, the number of cases of gonorrhoea 
in certain European Union (EU) and European Free 
Trade Association (EFTA) countries [4], including France 
[5], dropped significantly. This drop was the result of a 
reduction of at-risk sexual behaviours [6]. The advent 
of antiretroviral multitherapy in the mid-1990s brought 
with it a resurgence of these behaviours in the general 
population, especially in men who have sex with men 
(MSM). It also led to a resurgence in cases of gonor-
rhoea in some EU/EFTA countries [5,6] as well as in the 
United States [7].
In France, the epidemiological surveillance of gonor-
rhoea is based on two voluntary sentinel networks 
relying on clinicians (the RésIST network) or public and 
private laboratories (the Rénago network – National 
Gonorrhoea Network –) [8,9]. Since the beginning of 
the 2000s, an increase in gonococcal infections has 
been observed by these networks, both in men and 
women [9]. The RésIST network also highlighted that 
this increase exists irrespective of sexual orientation 
[8,9].
At the end of the 1990s and the beginning of the 2000s, 
concomitantly with the resurgence of gonoccocal infec-
tions, several countries reported increasing levels of 
gonococcal resistance to ciprofloxacin [2,10], a fluo-
roquinolone antibiotic, which was used at the time as 
a single-dose first-line treatment for uncomplicated 
urogenital gonorrhoea. Since the mid-2000s, single-
dose third generation cephalosporins (TGC), specifi-
cally oral cefixime and injectable ceftriaxone, became 
the only remaining recommendable antimicrobial class 
[11]. These treatments were officially recommended 
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in France at the end of 2005 [12]. However, the subse-
quent development of clinical and biological resistance 
to TGC, especially to cefixime, and, since the end of the 
2000s, to ceftriaxone, may lead to a therapeutic dead 
end in the coming years [2,11]. Surveillance of gono-
coccal susceptibility to these antibiotics is therefore 
essential.
Given this worrying context, the objective of this study 
was to describe the evolution of gonococcal infections 
and the changes in the susceptibility of gonorrhoea 
strains to antibiotics in France between 2001 and 2012. 
Factors associated with decreased susceptibility to 
TGC are also assessed.
Methods
The laboratories in the Rénago network are distributed 
throughout all of metropolitan France. This network 
helps monitor the resistance of Neisseria gonorrhoeae 
strains to antibiotics. Laboratory participation to sur-
veillance is voluntary.
The laboratories receive patients referred by their doc-
tor who prescribed a microbiological diagnosis for gon-
orrhoea. An anonymous epidemiological file, collected 
by the network laboratory microbiologist, provided 
the following information for each patient: sex, age, 
date of sample, anatomical site of sample, presence 
of symptoms, co-infection with another STI, probable 
country of infection, information on partner’s infection, 
the place of consultation and specialisation of treating 
physician, type of laboratory and geographical area to 
which it belongs. The sexual orientation of the patient 
is not reported. Information is consolidated and ana-
lysed by the Institut de Veille Sanitaire (InVS).
Figure 1
Geographical distribution of the 133 laboratories in the Rénagoa network according to participation in microbiological 
surveillance, France, 2012
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a Rénago is the national gonorrhoea network, a sentinel network based on voluntarily participating public and private laboratories.
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Because of the large proportion of missing data for four 
variables (presence of symptoms, co-infection with 
another STI, probable country of infection, and infor-
mation on patient’s partner infection status), the latter 
were used only for univariate analysis for descriptive 
purposes. All other variables were included in the mul-
tivariate analysis; p<0.05 was used as the level for sig-
nificance. Only the results of multivariate analysis are 
presented here, unadjusted and adjusted odds-ratios 
being very similar. For the analyses, the data concern-
ing the years from 2001 to 2009 were pooled to high-
light recent developments of the characteristics of 
gonococcal infections and of antibiotic susceptibility 
of strains in the period from 2010 to 2012.
Gonococcal infection is laboratory confirmed by a posi-
tive culture or a positive nucleic-acid amplification test 
(NAAT) for N. gonorrhoeae by the network laboratories. 
Strains isolated by culture by the network laborato-
ries are sent for antibiotic susceptibility testing to the 
Alfred Fournier Institute in Paris, which is the national 
reference laboratory (NRL) for gonorrhoea.
Because of the very high number of strains received by 
the NRL as well as budget constraints, the InVS and the 
NRL decided to separate epidemiological and microbio-
logical surveillance. Although the epidemiological data 
collection continued for all laboratories in the network, 
the number of laboratories sending their strains to the 
NRL was reduced by about fifty per cent from the begin-
ning of January 2012 (in 2012, 63 of the 133 laboratories 
in the network participated to the microbiological sur-
veillance). Nevertheless, a homogeneous geographical 
distribution of laboratories continuing this microbio-
logical surveillance was ensured (Figure 1).
The NLR determines the minimum inhibitory concen-
tration (MIC) for six antibiotics (penicillin G, tetracy-
cline, ciprofloxacin, spectinomycin, ceftriaxone, and, 
since 2008, cefixime) using Etest strips (first from AB 
Biodisk, Solna, Sweden; then from AES Laboratory, 
Combourg, France, and from May 2011 from i2a, 
Pérols, France). These antibiotics were or are still rec-
ommended for the treatment of gonorrhoea [11]. The 
presence of beta-lactamases is detected using Api NH 
(bioMérieux, Marcy-l’Etoile, France) identification test 
kits and, when there is any doubt, using a chromog-
enic cephalosporin test (cefinase, bioMérieux). The cri-
teria used to define resistance are those used by the 
European Committee on Antimicrobial Susceptibility 
Testing –EUCAST 2013 [13]. For TGC, no defined thresh-
old exists for resistance; strains with a MIC>0.125 mg/L 
for cefixime and for ceftriaxone are regarded as hav-
ing a decreased susceptibility. A strain was considered 
multi-resistant if it was resistant to penicillin G, tetra-
cycline and ciprofloxacin, and if the MIC for cefixime or 
for ceftriaxone was >0.125 mg/L.
The factors associated with a reduction in suscepti-
bility of gonorrhoea to TGC in patients aged at least 
15 years-old were determined through univariate and 
multivariate analyses using Stata v.11.0 software, 
excluding missing values. As the number of strains 
with MIC>0.125 mg/L for TGC was low, we studied the 
factors associated with a MIC≥0.094 mg/L for cefixime 
and a MIC≥0.032 mg/L for ceftriaxone. These values 
were chosen arbitrarily to have a sufficient number of 
strains with MICs above these cut-offs to allow com-
parison analyses. Taking into account such cut-offs, 
6% of strains had decreased susceptibility to these 
two antibiotics.
Results
Evolution of the number of gonococcal 
infections and analysed strains
Between 2001 and 2012, 13,400 cases of gonorrhoea 
were reported by the network’s laboratories. From 
these cases, a total of 10,501 strains were sent to the 
NLR. The NLR succeeded in recultivating 8,649 (82%) of 
them to determine the susceptibility of N. gonorrhoeae 
to antibiotics. The proportion of strains sent to the NLR 
and then recultivated remained quite stable from 2005 
to 2012 (84% on average for this period, range 82 to 
87%).
Figure 2 shows the increase in the number of reported 
cases and the number of strains studied by the NLR 
Figure 2
Annual number of reported gonococcal infections and 
strains tested by the national reference laboratory for 
gonorrhoea, Rénago networka, France, 2001–2012
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a  Rénago is the national gonorrhoea network, a sentinel 
network based on voluntarily participating public and private 
laboratories. All laboratories participate to the epidemiological 
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microbiological surveillance. In 2012, only 63 of the 133 
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Table 1
Characteristics of cases of gonorrhoea, Rénagoa network, France 2001–2012 (n=13,400)
Variables 2001–2009N (%)
2010
N (%)
2011
N (%)
2012
N (%)
Total 2001–2012
N (%)
Total 6,407 (100) 1,807 (100) 2,211 (100) 2,975 (100) 13,400 (100)
Sex
Male 5,552 (87) 1,506 (83) 1,718 (78) 2,044 (69) 10,820 (81)
Female 846 (13) 299 (17) 493 (22) 928 (31) 2,566 (19)
Not provided 9 (<1) 2 (<1) 0 (0) 3 (<1) 14 (<1)
Age (in years)
0–14 12 (<1) 8 (<1) 5 (<1) 21 (1) 46 (<1)
15–24 1,838 (29) 673 (37) 916 (41) 1,387 (47) 4,814 (36)
25–34 2,323 (36) 598 (33) 687 (31) 904 (30) 4,512 (34)
35–44 1,318 (21) 305 (17) 318 (14) 347 (12) 2,288 (17)
≥45 years 688 (11) 180 (10) 228 (10) 254 (9) 1,350 (10)
Not provided 228 (4) 43 (2) 57 (3) 62 (2) 390 (3)
Anatomical site
Urethra or urine 4,905 (77) 1,394 (77) 1,598 (72) 1,972 (66) 9,869 (74)
Cervix or vagina 745 (12) 278 (15) 459 (21) 839 (28) 2,321 (17)
Anus 588 (9) 98 (5) 105 (5) 77 (3) 868 (6)
Pharynx 35 (1) 8 (<1) 23 (1) 33 (1) 99 (1)
Other sites 112 (2) 24 (1) 25 (1) 35 (1) 196 (1)
Not provided 22 (<1) 5 (<1) 1 (<1) 19 (1) 47 (<1)
Presence of symptoms
Yes 4,336 (68) 1,099 (61) 1,365 (62) 1,739 (58) 8,539 (64)
No 127 (2) 97 (5) 93 (4) 160 (5) 477 (4)
Not provided 1,944 (30) 611 (34) 753 (34) 1,076 (36) 4,384 (33)
Co-infection with another STI
Yes 951 (15) 287 (16) 425 (19) 715 (24) 2,378 (18)
No 1,941 (30) 437 (24) 568 (26) 868 (29) 3,814 (28)
Not provided 3,515 (55) 1,083 (60) 1,218 (55) 1,392 (47) 7,208 (54)
Probable country of infection
France 1,691 (26) 502 (28) 576 (26) 719 (24) 3,488 (26)
Abroad 134 (2) 27 (1) 35 (2) 27 (1) 223 (2)
Not provided 4,582 (72) 1,278 (71) 1,600 (72) 2,229 (75) 9,689 (72)
Patient’s partner infected
Yes 212 (3) 76 (4) 102 (5) 124 (4) 514 (4)
No 122 (2) 38 (2) 47 (2) 90 (3) 297 (2)
Not provided 6,073 (95) 1,693 (94) 2,062 (93) 2,761 (93) 12,589 (94)
Place of consultation
Private sector or clinic 3,410 (53) 1,175 (65) 1,425 (64) 1,581 (53) 7,591 (57)
Hospital 1,203 (19) 274 (15) 316 (14) 462 (16) 2,255 (17)
Specialised facilities for STIsb 831 (13) 321 (18) 398 (18) 751 (25) 2,301 (17)
Other structures 0 (0) 9 (<1) 47 (2) 93 (3) 149 (1)
Not provided 963 (15) 28 (2) 25 (1) 88 (3) 1,104 (8)
Prescribing doctor
General practitioner 3,660 (57) 1,260 (70) 1,458 (66) 1,814 (61) 8,192 (61)
Gynaecologist 634 (10) 156 (9) 262 (12) 386 (13) 1,438 (11)
Dermatologist-venereologist 860 (13) 100 (6) 86 (4) 168 (6) 1,214 (9)
Other medical specialisation 877 (14) 256 (14) 320 (14) 381 (13) 1,834 (14)
Not provided 376 (6) 35 (2) 85 (4) 226 (8) 722 (5)
Type of Laboratory
Private 4,612 (72) 1,376 (76) 1,617 (73) 1,984 (67) 9,589 (72)
Hospital 1,610 (25) 352 (19) 500 (23) 804 (27) 3,266 (24)
Community clinic 185 (3) 79 (4) 94 (4) 187 (6) 545 (4)
Laboratory location (area in France)
Paris region 2,820 (44) 677 (37) 751 (34) 1,021 (34) 5,269 (39)
North-west 1,119 (17) 421 (23) 508 (23) 672 (23) 2,720 (20)
North-east 966 (15) 304 (17) 384 (17) 412 (14) 2,066 (15)
South-east 938 (15) 232 (13) 332 (15) 494 (17) 1,996 (15)
South-west 564 (9) 173 (10) 236 (11) 376 (13) 1,349 (10)
STI: sexually transmitted infection.
a Rénago is the national gonorrhoea network, a sentinel network based on voluntarily participating public and private laboratories.
b Specialised facilities for the management of STI: STI clinics, free anonymous counselling and testing services and family planning centres.
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between 2001 and 2012. During the first five years of 
the study, the number of laboratories participating in 
epidemiological surveillance greatly increased, from 
97 in 2001 to 151 in 2005. This number subsequently 
remained quite stable before decreasing between 
2011 (n=161) and 2012 (n=133). The yearly number of 
strains whose susceptibility was examined by the NLR 
increased tenfold from 150 in 2001 to 1,521 in 2011. In 
2012, with the number of participating laboratories to 
the microbiological surveillance decreasing by half, 
1,093 strains were tested.
Since 2009, larger numbers of diagnoses are being 
made using NAAT. NAAT accounted for only 6% 
(84/1,444) of microbiological diagnoses of gonorrhoea 
in 2009, this figure increased to 13% (237/1,807) in 
2010, 25% (554/2,211) in 2011 and 47% (1,408/2,975) 
in 2012. NAAT was exclusively used to diagnose 
gonorrhoea in 3% (40/1,444), 8% (136/1,807), 14% 
(302/2,211) and 28% (839/2,975) of patients, for each 
of these years, respectively (p<0.001, chi-square test 
for trend).
Epidemiological and clinical characteristics of 
cases of gonorrhoea
The clinical characteristics of reported cases of gon-
orrhoea are shown in Table 1. Most were male (81% 
over the whole study period: 10,820/13,400), yet the 
proportion of female constantly increased, reaching 
31% (928/2,975) of cases in 2012. The 15- to 24-year-
old age group was most affected, and saw a constant 
increase over time for both sexes. Median age was 
higher in men (29 years compared with 22 years in 
women; p<0.001, analysis of variance) over the whole 
study period, but decreased over time both in men and 
women (from, respectively, 30 and 24 years between 
2001 and 2009, to 26 and 21 years in 2012; p<0.001 for 
both comparisons).
Information on the presence of symptoms was miss-
ing for 33% (4,384/13,400) of cases. Considering those 
with such information available, 98% (7,587/7,720) 
of men and 73% (942/1,285) of women presented 
with symptoms (p<0.001). Information on simultane-
ous infection with another STI was missing in 54% 
(7,208/13,400) of cases. For cases with data, 32% 
(1,456/4,622) of men and 59% (918/1,561) of women 
had another STI (p<0.001), mainly co-infection with 
chlamydia (19%: 862/4,622 of co-infection in men and 
48%: 744/1,561 in women; p<0.001). Information on 
probable country of infection (i.e. in France or abroad) 
was missing in 72% (9,689/13,400) of cases. When it 
was available, infection had occurred outside of France 
in 7% (206/3,146) and 3% (17/561) of men and women, 
respectively (p=0.001). The partner’s infection status 
was hardly ever recorded by the laboratories, as the 
information was missing for 94% (12,589/13,400) of 
cases.
In men, samples were taken mainly from the urethra 
or urine (90%: 9,741/10,820). Samples from the anus 
(8%: 842/10,820 over the whole study period, dimin-
ishing in recent years to 4%: 72/2,044 in 2012) and 
pharynx (1%: 93/10,820) were much rarer. In women, 
samples were taken mainly from the cervix or vagina 
(90%: 2,320/2,566). Urethral (5%: 119/2,566) and anal 
(1%: 24/2,566) samples were also much rarer.
Patients had mainly consulted in private general prac-
titioner offices or in clinics (67%: 6,588/9,859 and 
41%: 1,000/2,424 of the men and women, respec-
tively, for whom information was available; p<0.001). 
Consultation had occurred less frequently in hospitals 
(17%: 1,632/9,859 and 26%: 621/2,424 of men and 
women, respectively; p<0.001) and less frequently in 
the following specialised facilities: STI clinics, free 
Anonymous Counselling and Testing Services and 
Family Planning Centres (15%: 1,521/9,859 and 32%: 
772/2,424 of men and women, respectively; p<0.001). 
The prescribing doctor was a general practitioner 
in most cases (71%: 7,236/10,244 of men and 39%: 
950/2,421 of women for whom information was avail-
able; p<0.001), a gynaecologist (50%: 1,209/2,421 of 
women) or a specialist in dermato-venereology (11%: 
1,127/10,244 and 3%: 83/2,421 of men and women, 
respectively; p<0.001).
Finally, bacteriological samples were mainly taken in 
private laboratories (74%: 7,992/10,820 of men and 
62%: 1,586/2,566 of women; p<0.001). They were less 
frequently collected in hospital laboratories (22%: 
2,384/10,820 and 34%: 879/2,566 of men and women, 
respectively; p<0.001) and rarely at a community clinic 
(4% of men: 444/10,820 and of women: 101/2,566; 
p=0.70).
Figure 3
Evolution of the resistance of gonococcal strains to 
penicillin G, tetracycline and ciprofloxacin, Rénagoa 
network, 2001–2012 (n=8,649 strains)
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Evolution of the susceptibility of gonococcal 
strains to antibiotics
The analysis is based on 8,649 gonococcal strains 
tested by the NLR. Proportionally, more strains were 
tested from men (70%: 7,569/10,815) than women 
(42%: 1,070/2,564; p<0.001). Furthermore anal sam-
ples were tested proportionally more often (84%: 
730/868) than samples from the other anatomical sites 
(63%: 7,898/12,478; p<0.001).
The majority of strains (73%:5,641/7,689) presented 
decreased susceptibility to penicillin G (MIC>0.064 
mg/L). The proportion of strains resistant to penicillin 
G (MIC>1 mg/L) fluctuated between 10 (12/126 in 2002) 
and 21% (109/512 in 2005; Figure 3, 13% on average: 
1,003/7,689) during the study period, with, in 2012, 
14% of strains resistant (148/1,093; 95% confidence 
interval (CI): 11.6–15.7). Nearly three quarters of resist-
ant strains (733/1,003) had a high level of plasmid-
mediated penicillin resistance (Table 2). 
The proportion of strains resistant to tetracycline 
increased from 29% (43/150) in 2001 to 56% (611/1,093) 
in 2012 (Figure 3). In 2012, 33% (366/1,093) of the 
Table 2
Evolution of the susceptibility of gonoccocal strains to antibiotics, Rénago networka, 2001–2012 (n=8,649 strains)
Antibiotics 2001–2009N (%)
2010
N (%)
2011b
N (%)
2012
N (%)
Penicillin G
Susceptible strains (MIC≤0.064mg/L) 1,251 (27) 383 (27) 130 (23) 284 (26)
Decreased susceptibility (0.064<MIC≤1mg/L) 2,741 (59) 863 (62) 373 (66) 661 (60)
Low-level chromosomal resistance (MIC>1mg/L and beta-
lactamase negative) 161 (3) 46 (3) 11 (2) 52 (5)
High-level plasmid-mediated resistance (beta-lactamase 
positive) 477 (10) 108 (8) 52 (9) 96 (9)
Total number of strains tested (N=7,689 strains) 4,630 (100) 1,400 (100) 566 (100) 1,093 (100)
Tetracycline
Susceptible strains (MIC≤0.5mg/L) 1,000 (22) 328 (23) 104 (18) 188 (17)
Decreased susceptibility (0.5<MIC≤1mg/L) 1,516 (33) 406 (29) 157 (28) 294 (27)
Low-level chromosomal resistance (1<MIC<16mg/L) 1,445 (31) 449 (32) 171 (30) 366 (33)
High-level plasmid-mediated resistance (MIC≥16mg/L) 670 (14) 217 (16) 132 (23) 245 (22)
Total number of strains tested (N=7,688 strains) 4,631 (100) 1,400 (100) 564 (100) 1,093 (100)
Ciprofloxacin
Susceptible strains (MIC≤0.064mg/L) 2,831 (61) 814 (58) 861 (57) 664 (61)
Decreased susceptibility (0.032<MIC≤0.064mg/L) 19 (<1) 2 (<1) 7 (<1) 1 (<1)
Low-level resistance (0.064<MIC<1mg/L) 200 (4) 53 (4) 117 (8) 19 (2)
High-level resistance (MIC≥1mg/L) 1,584 (34) 531 (38) 536 (35) 409 (37)
Total number of strains tested (N=8,648 strains) 4,634 (100) 1,400 (100) 1,521 (100) 1,093 (100)
Spectinomycinc
Susceptible strains (MIC≤64mg/L) 4,631 (100) 1,400 (100) 1,426 (100) 1,093 (100)
Total number of strains tested (N=8,550 strains) 4,631 (100) 1,400 (100) 1,426 (100) 1,093 (100)
Cefiximed
Susceptible strains (MIC≤0.125mg/L) 1,983 (100) 1,391 (99) 1,511 (99) 1,060 (97)
Decreased susceptibility (MIC>0.125mg/L) 8 (<1) 8 (1) 10 (1) 33 (3)
Total number of strains tested (N=6,004 strains) 1,991 (100) 1,399 (100) 1,521 (100) 1,093 (100)
Ceftriaxone
Susceptible strains (MIC≤0.125mg/L) 4,631 (100) 1,398 (100) 1,521 (100) 1,093 (100)
Decreased susceptibility (MIC>0.125mg/L) 0 (0) 2 (<1) 0 (0) 0 (0)
Total number of strains tested (N=8,645 strains) 4,631 (100) 1,400 (100) 1,521 (100) 1,093 (100)
Multidrug resistancee
No multidrug resistance 1,989 (100) 1,396 (100) 563 (100) 1,075 (98)
Multidrug resistant strains 1 (<1) 3 (<1) 1 (<1) 18 (2)
Total number of strains tested (N=5,046 strains) 1,990 (100) 1,399 (100) 564 (100) 1,093 (100)
EUCAST: European Committee on Antimicrobial Susceptibility Testing; MIC: minimum inhibitory concentration. 
EUCAST 2013 criteria were used for the definition of resistance [13].
a  Rénago is the national gonorrhoea network, a sentinel network based on voluntarily participating public and private laboratories.
b  In 2011, only 37% of strains were tested for penicillin G and tetracycline because of budgetary constraints.
c  For spectinomycin, precise analysis of MIC values was restricted to the period when the new E-test was used (from May 2011).
d  Cefixime was tested from 2008 onwards. There is no official threshold defining gonococcal resistance to third generation cephalosporins 
but 0.125 mg/L is used in practice [25].
e  Defined as resistance to penicillin G (MIC>1mg/L or beta-lactamase positive), tetracycline (MIC>1mg/L), and ciprofloxacin (MIC>0.064mg/L) 
and demonstration of elevated MICs of cefixime or ceftriaxone (MIC>0.125mg/L) [25].
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strains (95% CI: 31–36) had low-level chromosomal 
resistance and 22% (245/1,093; 95% CI: 20–25) had 
high-level plasmid-mediated resistance.
The proportion of strains resistant to ciprofloxacin 
(MIC>0.06 mg/L) increased sharply between 2003 
(15%: 30/195, 13%: 25/195 of which with high-level 
resistance (MIC≥1mg/L) and 2006 (47%: 243/514, 43%: 
221/514 of which with high-level resistance). It then 
remained quite high at around 42% (Figure 3). In 2012, 
2% (19/1,093; 95% CI: 1.0–2.7) of the strains had low-
level resistance while 37% (409/1,093; 95% CI: 35–40) 
had high-level resistance.
No strain resistant to spectinomycin was detected 
throughout the whole study period. The change in 
E-test type from May 2011 means that a comparison of 
the evolution of the distribution of MIC values before 
and after this date could not be made for this antibi-
otic. Nevertheless, the median MIC between 2001 (6 
mg/L) and 2011 until April (8 mg/L) remained relatively 
stable. Similarly, the median MIC remained stable 
between 2011 after May (16 mg/L) and 2012 (16 mg/L).
The proportion of strains with decreased susceptibil-
ity to cefixime (MIC>0.125 mg/L) was less than 1% until 
2011 (Table 2). In 2011 it was 0.7% (10/1,521; 95% CI: 
0.3–1.2) and increased significantly to 3.0% in 2012 
(33/1,093; 95% CI: 2.1–4.2; p<0.001). The proportion of 
strains with MIC values>0.094 mg/L increased consist-
ently between 2008 and 2012 (Figure 4).
In 2010, for the first time two strains of 1,400 (0.14%; 
95% CI: 0.02–0.57) showed decreased susceptibility to 
ceftriaxone, and both of these also showed decreased 
susceptibility to cefixime. Both cases were in men. One 
was about twenty years of age (MIC of 0.19 mg/L for 
ceftriaxone and 0.5 mg/L for cefixime). The other was 
a MSM in his fifties (MIC of 0.75 mg/L for ceftriaxone 
and 2 mg/L for cefixime) [14]. No decreased suscepti-
bility to ceftriaxone was subsequently found in 2011 or 
in 2012. The upward trend in MIC values between 2008 
and 2010 was not observed in the 2011 to 2012 period 
(Figure 5).
Finally, multidrug resistant strains were rare over the 
2001 to 2011 period (5/3,953: 0.1%; 95% CI: 0–0.3) 
but their proportion increased significantly in 2012 
(18/1,093: 1.6%; 95% CI: 1.0–2.6; p<0.001).
Restricted analysis of those laboratories which 
reported throughout the whole study period and con-
tinued to participate in microbiological surveillance 
during 2012 provided similar results in terms of the 
evolution of the susceptibility of gonococcal strains to 
antibiotics between 2001 and 2012 (data not shown).
Factors associated with a reduction in the susceptibil-
ity of gonococcal strains to third generation cephalo-
sporins in patients 15 years and older
Univariate analysis was performed using the variables 
from Table 1. The proportion of strains with decreased 
susceptibility to cefixime (MIC≥0.094 mg/L) and to cef-
triaxone (MIC≥0.032 mg/L) (Table 3) was significantly 
associated with age group, year of surveillance and 
Figure 4
Evolution of the distribution of minimum inhibitory 
concentration values for cefixime, Rénagoa network, 
2008–2012
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a Rénago is the national gonorrhoea network, a sentinel 
network based on voluntarily participating public and private 
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Figure 5
Evolution of the distribution of minimum inhibitory 
concentration values for ceftriaxone, Rénagoa network, 
2008–2012
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Table 3
Factors associated with decreased susceptibility of gonococcal strains to third generation cephalosporins in patients 15 
years-old and over, Rénago networka, 2001–2012 
Variables
Cefiximeb
MIC ≥0.094 mg/L
Ceftriaxonec
MIC ≥0.032 mg/L
n/N (%) ORa (95% CI) p n/N (%) ORa (95% CI) p
Years
2001–2009 80/1,988 (4) Ref. – 201/4,622 (4) Ref. –
2010 79/1,394 (6) 1.43 (1.03–1.99) 0.034 152/1,395 (11) 2.52 (2.00–3.18) <0.001
2011 110/1,520 (7) 1.78 (1.31–2.43) <0.001 111/1,520 (7) 1.54 (1.19–1.98) 0.001
2012 115/1,090 (11) 2.65 (1.94–3.62) <0.001 89/1,090 (8) 1.66 (1.26–2.19) <0.001
Sex
Men 332/5,217 (6) Ref. – 485/7,556 (6) Ref. –
Women 52/768 (7) 1.73 (0.69–4.35) 0.24 67/1,061 (6) 1.49 (0.66–3.35) 0.34
Age group in years
15–24 98/2,048 (5) Ref. – 147/2,717 (5) Ref. –
25–34 140/2,113 (7) 1.41 (1.08–1.86) 0.013 203/3,103 (7) 1.28 (1.02–1.60) 0.036
35–44 79/1,048 (8) 1.78 (1.30–2.45) <0.001 120/1,629 (7) 1.55 (1.19–2.01 0.001
≥45 60/659 (9) 1.97 (1.39–2.78) <0.001 72/951 (8) 1.49 (1.10–2.02) 0.010
Anatomical site
Urethra or urine 309/4,784 (6) Ref. – 435/6,763 (6) Ref. –
Cervix or vagina 45/690 (7) 0.56 (0.21–1.47) 0.24 58/949 (6) 0.69 (0.29–1.61) 0.39
Anus 19/392 (5) 0.88 (0.51–1.52) 0.65 43/729 (6) 1.19 (0.81–1.73) 0.37
Pharynx 7/35 (20) 4.21 (1.62–10.91) 0.003 7/52 (13) 2.86 (1.17–6.99) 0.021
Other sites 4/78 (5) 0.71 (0.22–2.28) 0.56 8/113 (7) 0.96 (0.41–2.26) 0.93
Place of consultation
Private sector or clinic 286/3,994 (7) Ref. – 382/5,365 (7) Ref. –
Hospital 39/883 (4) 0.55 (0.30–1.00) 0.052 89/1,459 (6) 1.13 (0.71–1.79) 0.60
Specialised facilities for STIsd 51/983 (5) 0.77 (0.48–1.23) 0.28 68/1,276 (5) 0.86 (0.60–1.25) 0.44
Other structures 4/36 (11) 1.07 (0.32–3.58) 0.92 3/36 (8) 0.67 (0.16–2.85) 0.59
Prescribing doctor
General practitioner 276/4,198 (7) Ref. – 379/5,634 (7) Ref. –
Gynaecologist 28/363 (8) 1.18 (0.68–2.07) 0.55 35/587 (6) 1.38 (0.90–2.11) 0.14
Dematologist-venereologist 20/358 (6) 1.43 (0.83–2.47) 0.20 37/760 (5) 0.98 (0.61–1.57) 0.93
Other medical specialisations 50/903 (6) 1.19 (0.76–1.84) 0.45 85/1,288 (7) 1.13 (0.79–1.61) 0.51
Type of laboratory
Private 308/4,501 (7) Ref. – 428/6,349 (7) Ref. –
Hospital 63/1,251 (5) 1.19 (0.71–1.94) 0.52 107/1,966 (5) 0.72 (0.48–1.08) 0.12
Community clinic 13/240 (5) 1.24 (0.60–2.56) 0.56 18/312 (6) 0.98 (0.52–1.83) 0.94
Laboratory location (area)
Paris region 96/2,073 (5) Ref. – 170/3,379 (5) Ref. –
North-west 86/1,324 (6) 1.36 (0.98–1.90) 0.07 111/1,747 (6) 1.27 (0.97–1.67) 0.09
North-east 107/1,095 (10) 1.99 (1.45–2.73) <0.001 154/1,451 (11) 2.23 (1.73–2.87) <0.001
South-east 54/881 (6) 1.06 (0.72–1.56) 0.76 70/1,226 (6) 1.08 (0.78–1.49) 0.65
South-west 41/619 (7) 1.23 (0.81–1.85) 0.33 48/824 (6) 1.11 (0.78–1.60) 0.56
MIC: minimum inhibitory concentration; ORa: odds ratio adjusted for the other variables in the table; 95% CI: 95% confidence interval; ref.: 
reference group; STIs: sexually transmitted infections. 
For each variable, the number of strains with decreased susceptibility (n) is given relative to the total tested for the antibiotic (N) as well as 
the percentage. The multivariate analysis includes all the variables in the Table. Significant results (p<0.05) are in bold.
a  Rénago is the national gonorrhoea network, a sentinel network based on voluntarily participating public and private laboratories.
b  Cefixime tested from 2008 onwards; MIC≥0.094 mg/L for 385 strains of 6,004 (6.4%).
c  Ceftriaxone: MIC≥0.032 mg/L for 554 strains of 8,645 (6.4%).
d  Specialised facilities for the management of STI: STI clinics, free anonymous counselling and testing services and family planning centres.
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geographical area. This proportion was also greater 
in the absence of gonorrhoea-associated STI, nota-
bly in the absence of co-infection with chlamydia. 
Furthermore the proportion of strains with decreased 
susceptibility to cefixime was associated with anatomi-
cal site of sample, presence of symptoms and place of 
consultation.
Multivariate analysis (Table 3) was performed using 
the variables from Table 1 excluding four variables with 
a large proportion of missing data (as mentioned in 
the methods section). The proportion of strains with 
decreased susceptibility to cefixime (MIC≥0.094 mg/L) 
increased in the 2010 to 2012 period. Indeed, this 
proportion was 2.7 times greater in 2012 than for the 
period between 2001 and 2009. This reduced suscep-
tibility increased with the patients’ age. It was almost 
four times higher for strains derived from the pharynx 
than for those derived from the urethra, even when 
analysis was restricted to male patients (adjusted 
odds ratio 4.2; 95% CI: 1.5–11.6; p=0.006). Finally, the 
decrease in susceptibility to cefixime was found to be 
higher in the north-eastern area of France.
The proportion of strains with decreased susceptibility 
to ceftriaxone increased in the 2010 to 2012 period, this 
increase being particularly sharp in 2010. Taking 2010 
as the reference year, the proportion of strains with 
decreased susceptibility to ceftriaxone (MIC≥0.032 
mg/L) significantly diminished in the 2011 to 2012 
period. As was the case for cefixime, decreased sus-
ceptibility for ceftriaxone increased with patients’ age, 
was higher for pharyngeal-based strains (even when 
restricting the analysis to male patients) (adjusted 
odds ratio: 3.4; 95% CI: 1.4–8.2; p=0.008) and was 
higher in the north-eastern area of France.
Multivariate analysis of the 2001 to 2012 period, 
restricted to the laboratories which continued microbi-
ological surveillance in 2012, provided similar results 
(data not shown).
Discussion
The microbiological surveillance network in France 
shows that the proportion of resistant strains to anti-
biotics fluctuated around 13% for penicillin G over the 
whole study period. It increased throughout the study 
for tetracycline, reaching 56% in 2012. For ciprofloxa-
cin it increased between 2003 and 2006 after which it 
remained high at around 42%. These three families of 
antibiotics have a resistance level which prevents them 
from being used in current practice for the treatment 
of gonorrhoea. Indeed, according to the World Health 
Organization, first-line treatment must cure at least 
95% of patients and must not be used if more than 5% 
of strains are resistant [2].
Gonorrhoea was susceptible to spectinomycin 
throughout the study period. The marketing of this 
antibiotic in France stopped in 2008 and then started 
again since 2011. However, therapeutic failures for 
pharyngeal-based infections have led it to become a 
second-line treatment when there are contraindica-
tions to beta-lactam antibiotics [15].
The proportion of strains with decreased susceptibil-
ity to cefixime (MIC>0.125 mg/L) remained moderate, 
less than 5%, but it quadrupled between 2011 and 
2012. Furthermore, the proportion of isolates with 
high MIC values (MIC≥0.094 mg/L) increased consist-
ently in recent years (Figure 4 and Table 3). The only 
two strains presenting MICs>0.125 mg/L to ceftriaxone 
were both detected in France in 2010, and one of these 
was associated with therapeutic failure using cefixime 
in an infected patient [14]. With respect to ceftriaxone, 
the number or proportion of isolates with high MIC val-
ues (MIC≥0.032 mg/L) did not increase in 2011 or 2012. 
The very rare cases of decreased susceptibility to cef-
triaxone [14,16-19] and cases of therapeutic failure 
with cefixime described in Japan, Canada and Europe 
[14,20-23], confirm the recommendations made by the 
French Agency for Medicine published in 2005 [12], 
which were reaffirmed in 2008 [15]. These guidelines 
recommend the use of ceftriaxone (500 mg single-
dose injection) in first-line treatment, and that the use 
of cefixime (400 mg single-dose oral) be reserved for 
cases of patient refusal or when parenteral treatment 
is not possible.
Nevertheless, the increase in gonococcal decreased 
susceptibility to cefixime observed in France suggests 
that clinicians may have continued to prescribe this 
antibiotic as a first-line treatment after the recom-
mendations of 2005 were published (and reaffirmed 
in 2008). Indeed, a study performed in 2008 on gen-
eral practitioners in the ‘Sentinelles’ network showed 
that only a minority of prescribing doctors were aware 
of the 2005 recommendation to abandon ciprofloxacin 
in favour of TGC [24]. By analogy, it is possible that 
in 2012 doctors had not yet sufficiently implemented 
the recommendation reiterated in 2008 regarding the 
use of TGCs [15]. A new study on doctors’ prescriptions 
could help support this hypothesis. Another hypothe-
sis to explain the recent increase in gonococcal resist-
ance to cefixime is the spread of a resistant clone [25].
The levels of resistance to penicillin G, tetracycline 
and ciprofloxacin in France were higher than those 
found in the United States, but of the same order for 
TGC and multidrug resistance [26]. In contrast, the lev-
els of resistance in France were of the same order as 
European levels for penicillin G and ciprofloxacin, but 
lower for TGC [27].
We currently do not have data on the susceptibility of 
gonorrhoea to azithromycin. In France this antibiotic is 
taken in a single, 1 g dose with ceftriaxone in suspected 
cases of urethritis and cervicitis [12,15]. Elsewhere, 
notably in the United States, azithromycin is recom-
mended in monotherapy for gonococcal infections, in 
the case of allergies to TGC [28]. Because of resistance 
to azithromycin described in various countries [26,29] 
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this antibiotic is being tested within the Rénago net-
work as of 2013.
Our study shows factors associated with a reduction 
in the susceptibility to TGC. We acknowledge that the 
combination of data from 2001 to 2009 only allowed to 
highlight the recent epidemiological and microbiologi-
cal changes. The proportion of strains with decreased 
susceptibility to TGC increased with patients’ age. 
This has already been observed for other antibiotics 
(penicillin and tetracycline) in Canada [29]. A lower 
proportion of gonococcal resistant strains in the case 
of co-infection with chlamydia was found for cefixime 
in the United Kingdom [30] and for ciprofloxacin at the 
European level [27], although the reason for this is not 
clearly established.
The proportion of strains with decreased susceptibil-
ity to TGC did not differ significantly according to sex. 
Anal-based strains did not present higher decreases 
in susceptibility than urethral-based strains. However, 
the proportion of pharyngeal-based strains with 
decreased susceptibility to TGC was three to four 
times higher than urethral-based strains. This may be 
explained by the horizontal transfer of gene mutations 
associated with decreased susceptibility to TGC from 
oral commensal Neisseria [31]. Anal and pharyngeal 
gonorrhoea in men was probably acquired through 
homosexual transmission, although the absence of 
information on sexual behaviours from the Rénago 
network prevents us from being certain about this. 
Several studies have shown that MSM are likely to be 
infected more frequently and more quickly than het-
erosexuals by resistant gonococcal strains [26,30,32]. 
This fact highlights the need for specific surveillance 
of antibiotic susceptibility in MSM. We found that the 
monitoring of anal strains brought information on 
resistance similar to those of urethral strains. Despite 
the absence of behavioural data, our study shows, 
however, that increased monitoring of pharyngeal-
based strains with respect to decreased susceptibility 
to TGC seems essential.
Finally, we observed a higher level of decreased sus-
ceptibility in the north-eastern area of France. It is hard 
to interpret the reason for this. Obviously this area 
should remain under close scrutiny, while still keeping 
the national distribution of the network’s laboratories 
homogeneous.
In the Rénago network, an increase in the number of 
declared gonococcal infections occurred over the 2001 
to 2012 period. Several interlinked phenomena contrib-
uted to this: the real growth in infections, the increase 
in NAAT diagnoses, the increase in the number of par-
ticipating laboratories and the growing shift towards 
the consolidation of laboratories. Despite this complex 
evolution, the Rénago network continued to help moni-
tor gonococcal resistance to antibiotics. This micro-
biological surveillance network would appear to be 
reliable as the changes that have been made to it have 
(the reduction by half of the number of laboratories 
submitting strains to the NRL), a priori, had little or no 
effect on the proportion of resistant strains observed. 
Restricted analysis to those laboratories which con-
tinued to participate in microbiological surveillance in 
2012 provides strong evidence for this.
The surveillance of gonococcal resistance by the 
Rénago network brings with it several limitations. 
Overseas French regions are not yet included in sur-
veillance. Furthermore, the laboratories participating 
in the network do not provide a representative sample 
of metropolitan France. Extrapolation of the results 
therefore requires supplementary investigations. An 
assessment of the completeness of this laboratory 
surveillance system is ongoing but results are not yet 
available. Finally, this network does not collect behav-
ioural data as microbiologists do not often have access 
to such information. This explains the large amount of 
missing values for certain variables. One way for us to 
have behavioural data, in particular sexual orientation, 
is to monitor the susceptibility of gonococcal strains in 
patients diagnosed through our second voluntary net-
work, the RésIST network of clinicians.
The emergence of resistance to TGC is extremely wor-
rying as the latter represent the last line of treatment, 
with no therapeutic alternatives currently available 
[31]. This fact justifies the continuation of microbio-
logical surveillance of gonorrhoea at a collective 
level in order to adjust therapeutic recommendations. 
Meanwhile, surveillance of therapeutic failure with 
respect to TGC is currently being implemented at the 
European level [33]. Given the increase in NAAT diag-
nosis, it is essential that medical laboratories continue 
to perform gonococcal cultures which adapt care to the 
individual’s needs while waiting for molecular tests on 
susceptibility to antibiotics to be developed and made 
accessible [2].
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Long-term surveillance of Echinococcus multilocularis 
occurrence in red foxes in Slovakia revealed the exist-
ence of highly endemic areas, with an overall preva-
lence rate of 41.6 % in the northern part of the country. 
Between 2000 and 2013, 26 human cases of alveolar 
echinococcosis were detected and only three of them 
were not in endemic localities in northern Slovakia. 
Remarkable is the occurrence of the disease in eight 
people younger  than 35 years, including three patients 
aged eight, 14 and 19 years. Occurrence of E. multi-
locularis in red foxes throughout the country and high 
incidence of alveolar echinococcosis in young people 
indicate high infectious pressure in the environment 
of northern Slovakia. It can be assumed that the real 
incidence of alveolar echinococcosis is significantly 
higher than recorded by official data due to the lack of 
existing registration and reporting system. For effec-
tive management of prevention and control strategies 
for this disease improvement of the national surveil-
lance system and engagement of specialists outside 
the medical community are necessary. Our study pre-
sents a comprehensive picture of the epidemiological 
situation of E. multilocularis in northern Slovakia. In 
addition, we report the first list of confirmed human 
cases of this serious parasitosis in Slovakia.  
Introduction
Echinococcus multilocularis, causative agent of alveo-
lar echinococcosis in humans, has become the target 
of intensive research at the beginning of the 1980s 
[1]. In the past decades, the known range of the par-
asite in Europe has expanded. The formerly known 
geographical range of the parasite included regions 
of (by date of detection) Austria, Switzerland, France, 
Germany, Liechtenstein, Luxembourg, Denmark, the 
Baltic states, Belgium, the Netherlands, northern 
Italy, Poland, the Czech Republic, Slovakia, northern 
Hungary and Slovenia [2,3]. Recently, the occurrence of 
E. multilocularis was for the first time confirmed also 
in Sweden [4,5], and in southern Denmark, a new high-
endemic focus was detected [6]. The importance of the 
issue is highlighted by a recent regulation issued by 
the European Commission in 2011 [7]. The aim of the 
measures outlined in the regulation is to minimise the 
risk of introducing the parasite into territories where it 
has not yet been detected, namely Finland, the United 
Kingdom, Ireland and Malta [7].
In Slovakia, E. multilocularis was detected for the first 
time in red foxes in 1999 [8] and intensive epidemio-
logical studies have been carried out since. During 
the surveillance of E. multilocularis between 2000 and 
2010, more than 4,700 red foxes (Vulpes vulpes) from 
all regions of the country have been examined. The 
total average prevalence of the parasite was 30.3% 
and the existence of highly endemic areas in northern 
regions of Slovakia was revealed [9].
The survey presents a comprehensive picture of the 
epidemiological situation of E. multilocularis in highly 
endemic regions of northern Slovakia from its first 
detection in 1999 until 2012 and includes results from 
the territory of the High Tatras National Park. Moreover, 
we report here the first list of confirmed human cases 
of this serious parasitic disease.
Methods
Collection and examination of red foxes
Monitoring of E. multilocularis in red foxes living in 
northern Slovakia (Žilina and Prešov Region includ-
ing the High Tatras National Park) was conducted in 
the years 2000 to 2005, 2007, and 2010 to 2012. Red 
foxes were collected in the framework of the control 
of the effectiveness of anti-rabies vaccination carried 
out twice a year, in spring/summer and autumn/win-
ter campaigns. The number of samples and the time 
schedule of campaigns were set by the State Veterinary 
and Food Administration of the Slovak Republic. From 
each of 79 Slovak districts, a representative sample 
of at least six foxes per campaign was shot. Animals 
originating from the protected area of the High Tatras 
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National Park were found dead, road-killed or legally 
hunted by workers of the Tatra National Park Research 
Station. Small intestines of the animals were deep-
frozen at -80°C prior to necropsy and parasitological 
examination. Sedimentation and counting method [10] 
with modification of using 0.09 mm mesh analytic 
sieves for washed fraction filtration [9] was applied for 
E. multilocularis detection.
Climatic data collection
Influence of climatic factors (mean annual air tempera-
ture and mean annual precipitation) on the prevalence 
rate of E. multilocularis in red foxes in individual years 
was assessed. The data were obtained from datasets 
of Statistical Office of the Slovak Republic [11].  Data 
measured at three weather observatories in northern 
Slovakia (Oravská Lesná – Žilina Region, Poprad and 
Stropkov – Prešov Region) were used for this purpose.
Collection and examination of dog samples for 
Echinococcus multilocularis
To determine the role of dogs in the spread of the dis-
ease in highly endemic areas, 138 animals originat-
ing from the northern areas of Slovakia (Prešov and 
Žilina Region) were collected between 2002 and 2005. 
Faecal samples came from stray and owned dogs that 
were not dewormed regularly with the last deworming 
treatment at least four months before examination. In 
order to reduce the risk of infection, all samples were 
deep-frozen at -80 °C for at least seven days prior to 
examination.
Data concerning the age, sex, locality and usage of 
dogs were gathered with the help of a questionnaire. 
Other questions were related to how often the dogs 
could move freely in rural areas, were fed with raw vis-
cera or caught rodents. Animals aged up to 10 months 
were classified as young, older animals were identified 
as adults.
Nested PCR was used to detect the presence of E. mul-
tilocularis DNA in faecal samples [12].
Statistical analyses
The prevalence of E. multilocularis in the examined dog 
and red fox population was calculated. The seropreva-
lence values were given with 95% confidence intervals 
(CI), and odds ratios (OR) were calculated to estimate 
the association between variables included in the 
study (age, sex, utilisation, etc.) and the risk of echino-
coccosis. All statistical analyses were conducted using 
STATISTICA 6 Base (StatSoft, Inc, 2001).
Sampling and diagnostics of alveolar 
echinococcosis in humans
Human samples and data about the patients were 
collected in cooperation with medical doctors and 
hospitals, especially with infectious disease and sur-
gical clinics from different regions in Slovakia. Sera 
from patients suspected for echinococcosis, e.g. 
patients with clinical symptoms of echinococcosis 
or patients with cystic lesions found during imaging 
examination (ultrasonography (USG), radiography, 
computed tomography (CT)) were sent to the Institute 
of Parasitology SAS (IP SAS) for serological examina-
tion. At the beginning, IP SAS was the only laboratory 
where antibodies to Echinococcus could be examined. 
After a few years, private laboratories started with 
serological diagnostics and it could not be estimated 
how many samples were sent elsewhere. Currently, 
IP SAS is the only laboratory performing Western blot 
and PCR tests. Specific antibodies to E. multilocularis 
were detected by modified ELISA [13,14] or commercial 
ELISA test kits (NovaLisa Echinococcus IgG, NovaTec 
Immunodiagnostica, Germany), and positive sera of 
patients who had not undergone surgery, i.e. for whom 
PCR samples or histology were not available, were 
examined also by Western blot (Echinococcus WB IgG, 
LDBIO Diagnostics, France). Imaging techniques (USG, 
CT, magnetic resonance imaging (MRI)) were performed 
to detect the presence of parasitic lesions in the liver 
and other organs, and material obtained during surgery 
was submitted to histological and/or PCR examination 
[15]. Some clinical cases were detected accidentally, 
during surgical intervention for another disease.
The diagnosis was confirmed if at least two of follow-
ing four parameters were verified [16]: (i) typical organ 
lesions detected by imaging techniques, (ii) presence 
of antibodies to Echinococcus multilocularis (ELISA, 
Western Blot), (iii) histological findings compatible 
with E. multilocularis metacestode, or (iv) detection of 
E. multilocularis DNA by PCR methods.
Results
Surveillance of Echinococcus multilocularis in 
red foxes in northern Slovakia during 2000 to 
2012
Since 2000, a total of 1,875 red foxes originating from 
the northern Slovak regions have been examined for E. 
multilocularis presence. The tapeworm was detected 
in the small intestines of 779 foxes (41.6 %), with a 
mean prevalence rate in the Žilina and Prešov Region 
of 47.7% and 38.5%, respectively (Figure 1).
The annual prevalence varied between 26.0% in 2007 
and more than 50.0% in 2001, 2005 and 2010. The 
mean worm burden reached 2.352 tapeworms per 
infected fox (Table 1).
Considerable correlation was observed between prev-
alence of E. multilocularis in red foxes and the mean 
annual air temperature, as well as between prevalence 
and mean annual precipitation. The prevalence reached 
the highest values (50.8–58.4%) during the cold and 
wet years of 2001, 2005 and 2010 (Figure 2). In con-
trast, prevalence significantly decreased (to 30.2%, 
26.0% and 27.3%, respectively) in the much drier years 
2003, 2007 and 2012 (Table 1) [17].
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Echinococcus multilocularis in dogs
Of 138 dog faeces examined, E. multilocularis DNA 
was confirmed in four (2.9 %) samples. The majority, 
119 samples, came from the Prešov Region with three 
infected animals (2.5 %). Among the 19 animals from 
the Žilina Region, one sample (5.2 %) was found to be 
positive.
The positive animals were used as guard and shepherd 
dogs, but neither usage of the dogs nor their age or 
sex influenced the occurrence of parasites significantly 
(p>0.05).
Data about free movement in rural areas, feeding and 
catching rodents were known for 82 cases. Positivity 
for E. multilocularis was closely correlated with the 
possibility to catch the rodents (p=0.04; OR=9.4; 95% 
CI: 0.9–95.9) and uncontrolled movement in rural areas 
(p=0.02; OR=14.5; 95% CI: 1.4–145.5). Feeding with 
raw viscera was not identified as a risk factor for infec-
tion (Table 2).
Human cases of alveolar echinococcosis in 
Slovakia
The first case of alveolar echinococcosis in Slovakia 
was confirmed in 2000 in a woman in her 60s from a 
village in the Žilina Region (north-western Slovakia). 
Figure 1
Occurrence of alveolar echinococcosis in humans (n=26) and mean prevalence of Echinococcus multilocularis in red foxes in 
the Žilina and Prešov Regions, Slovakia 2000–2012 
Locations of human cases are indicated as dots. Echinococcus multilocularis prevalence in foxes is indicated in square brackets.
AT: Austria; CZ: Czech Republic; HU: Hungary; PL: Poland; UA: Ukraine.
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Although the first clinical symptoms of the disease 
had appeared already in 1994, the lack of knowledge 
about the presence of E. multilocularis on the territory 
of Slovakia probably resulted in misdiagnosis. In the 
patient’s anamnesis, a history of keeping a dog and 
collecting forest fruits were of epidemiological impor-
tance [18].
In the same year, a second case of autochthonous 
alveolar echinococcosis was detected. The patient was 
a woman in her 70s, from a village in mountain area 
of north-western Slovakia (Žilina Region), who spent 
a lot of time at her mountain cottage where she grew 
vegetables. Except weight loss, the patient had no 
clinical signs, and the disease was noticed only after 
observing the high erythrocyte sedimentation rate 
during a routine medical examination. Subsequent 
USG and CT examination of the abdomen revealed an 
irregularly shaped focus 12x11x10 cm in the right liver 
lobe. Serological (ELISA, Western blot) and histological 
examinations confirmed the diagnosis of alveolar echi-
nococcosis [19].
Three years later, in 2004, two further cases were 
verified. The patients were men from the Prešov and 
Žilina Region. Since then, new cases of alveolar echi-
nococcosis have been detected every year (Figure 
3). The incidence of the disease has followed an 
increasing trend. As of April 2013, the total number 
of alveolar echinococcosis in Slovakia has reached 
26 cases (Figure 1). Only three of these patients did 
not come from the highly endemic Prešov or Žilina 
Regions. One woman came from the Trenčín Region, 
situated in the west of Slovakia and neighbouring the 
Žilina Region, and two persons were from the Košice 
Region neighbouring the Prešov Region (Figure 1). The 
mean age of the patients was 52.3±20.7 years, rang-
ing between eight and 78 years. Only negligible differ-
ences were recorded between the positivity of women 
(14 cases) and men (12 cases).
In addition to the 26 confirmed cases of alveolar echi-
nococcosis, at least 10 other cases were detected 
between 2007 and 2012 in whom the aetiological 
agent of echinococcosis was not determined. In these 
patients, the diagnosis of echinococcosis was made 
after serological and USG examination. However, mate-
rial for histological or PCR examination that could 
facilitate the confirmation of diagnosis could not be 
obtained because of the good response to anthelmin-
tic treatment that made surgical intervention unneces-
sary, or because the patients neglected to appear for 
their control examination.
Three of the 26 confirmed patients were younger than 
20, one of them even younger than 10 years (Table 3). In 
2006, alveolar echinococcosis was diagnosed in a teen-
ager from the Prešov Region, living in close vicinity of 
Table 1
Occurrence of Echinococcus multilocularis in red foxes, northern Slovakia, 2000–2012
Year Mean annual air temperaturea (°C)
Mean annual 
precipitationsa 
(mm)
Number of foxes 
examined
Number of foxes 
infected
Prevalence % 
(range)
Mean worm 
burden
Number per fox 
(range)
2000 7.7 902.1 175 48 27.4(19.0 –36.3) NA
2001 6.7 962.8 185 108 58.4 (48.8–67.5)
1,426
(1–25.000)
2002 7.4 865.7 175 90 51.4(42.2–60.6)
1,930
(2–40.000)
2003 6.8 629.6 301 91 30.2(25.6–35.3)
495
(1–10.500)
2004 6.5 895.7 247 108 43.7(43.7–39.0)
1,497
(1–16.000)
2005 6.0 949.2 333 169 50.8(45.2–56.3)
5,013
(2–59.900)
2007 6.8 701.0 158 41 25.9(18.9–34.1)
11,027
(5–245.000)
2010 6.5 1,155.2 122 68 55.7(48.1–63.1)
1,093
(1–19.900)
2011 NA NA 58 23 39.7(29.6–50.3)
1,096
(2–37.920)
2012 NA NA 121 33 27.3(20.1–35.0)
3,232
(3–33.120)
Total - - 1,875 779 41.6 2,352(1–245.000)
NA: data become available in full-scale form with a delay of two years. 
a Measured at three weather observatories in northern Slovakia (Oravská Lesná, Poprad, Stropkov).
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a forest. The patient suffered from headache, fatigue, 
cough, fever and abdominal enlargement. USG exami-
nation confirmed tumour-like infiltrations in the right 
and left liver lobes and the diagnosis of echinococcosis 
was confirmed by ELISA, Western blot and histological 
examination [20]. In 2012, two more cases of alveolar 
echinococcosis in young patients were detected. One 
was a teenager from the Žilina Region with multiple 
cysts in the liver and four cysts in the lungs, found 
by USG examination; the diagnosis was confirmed by 
PCR after the resection of suspicious parasitic material 
from the liver. The other case was younger and came 
from the Prešov Region, with a primary infection site 
in the right femur; no other lesions were confirmed 
using USG and PET-CT examinations. This case was 
living near the forest at the end of a village, in close 
vicinity to an area often visited by red foxes. The family 
also owned a dog. Although the first symptoms, pain in 
the right leg and knee, were not indicative of alveolar 
echinococcosis, serological examination confirmed the 
presence of antibodies to Echinococcus spp. Following 
histological investigation of material obtained during 
surgical intervention, Western blot of the serum sam-
ple and PCR analyses of DNA from the cyst secretion 
confirmed the diagnosis of alveolar echinococcosis.
Discussion and conclusion
Our monitoring confirms the presence of highly 
endemic areas of E. multilocularis in the northern part 
of Slovakia, with a mean prevalence rate of almost 
42.0% in its main definitive hosts, red foxes. This 
12-year examination of red foxes has unfolded great 
fluctuation of E. multilocularis prevalence between 
years, probably depending on climatic conditions. 
Prevalence rates were highest during the cold and wet 
years of 2001, 2005 and 2010. In those years precipi-
tation totals were considerably above normal. In con-
trast, prevalence significantly decreased in the warmer 
years of 2003, 2007 and 2012, which were the first, 
third and fourth warmest years since 1871 in Slovakia 
[17].
Given that E. multilocularis is considered a parasite 
adapted to cold climate, environmental conditions of 
northern Slovakia are very suitable for the spread of 
echinococcosis. The area is characterised by mountain 
climate with average annual temperatures between -3 
and +4 °C. Annually, rainfall varies between 800 and 
2000 mm. Main recreational areas of Slovakia are situ-
ated in northern Slovakia, which is of relevance from 
a public health point of view. Žilina Region is domi-
nated by national parks, and 51.0% of its territory is 
under some form of protection, accounting for 30.0% 
of Slovakia’s total protected area. In the territory of the 
Prešov Region are situated the only truly alpine moun-
tains in Eastern Europe, the Tatra National Park [11]. In 
the past decades, touristic activities have increased, 
not only in the National Parks but all over the coun-
try.  The estimated number of tourists visiting Tatra 
National Park exceeds 3,500,000 per year [21]. In addi-
tion, the risk of human infection is also influenced by 
high population density and urbanisation of red foxes 
(and other free-living carnivores) in these areas.
Due to close contact with humans and contamination 
of soil around houses and in gardens, dogs present a 
considerable risk factor in the spread of echinococco-
sis to humans. Stehr-Green et al. and Kern et al. identi-
fied ownership of a dog as associated with acquisition 
Figure 2
Positive correlation between Echinococcus multilocularis 
prevalence in red foxes and mean annual precipitationa, 
northern Slovakia, 2000–2010
a Measured at three weather observatories (Oravská Lesná, 
Poprad, Stropkov).
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Table 2
Impact of usage, feeding and catching rodents on the 
occurrence of Echinococcus multilocularis in dogs, 
2000–2005
Variable Positive/examined (%) 95% CI
Usage
Hunting dogs 0 / 47 (0.0) −2.8 to 13.5
Guard dogs 2 / 35 (5.7) 1.1–17.4
Shepherd dogs 2 / 26 (7.7) 1.4–24.6
Pet dogs 0 / 11 (0.0) 0.0–26.4
Unknown 0 / 19 (0.0) 0.0–17.6
Fed with raw viscera
Yes 3 / 26 (11.5) 3.2–30.2
No 1 / 41 (2.4) −0.5 to 14.5
I don’t know 0 / 15 (0.0) 0.0–22.2
Catching rodents
Yes 3 / 17 (17.6) 4.9–41.7
No 1 / 54 (1.9) 0.2–7.4
I don’t know 1 / 11 (0.1) 0.5–40.4
CI: confidence interval.
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of the disease [22,23]. Some of the dogs (2.9%) in our 
study were infected with E. multilocularis and could 
be a source of human infection. Catching rodents and 
unattended movement in rural areas were correlated 
with infection of dogs. Of course, a larger number of 
samples and further epidemiological analyses would 
be more valuable, but due to limited staff we did not 
continue the examination of dogs after 2005. Budke et 
al. and Ziadinov et al. also recognised a higher prob-
ability of infection in dogs that hunt rodents, in hunt-
ing dogs and in non-restrained dogs [24,25]. Although 
E. multilocularis is not common in dogs in Slovakia, 
contact with animals with risk behaviour increases the 
probability of infection, especially in highly endemic 
regions of the country.
The list of diagnosed human cases of alveolar echino-
coccosis confirms northern Slovakia as a risk area. Of 
26 infected humans, only three lived outside the Žilina 
or Prešov Region. However, the prevalence of E. multi-
locularis in red foxes also reaches 18.4 % in the Košice 
Region and as much as 40.3 % in the Trenčín Region 
[9]. Thus, the risk of infection in areas in regions other 
than Žilina and Prešov is not negligible and a rise in 
the number of new cases is possible in the future. 
Moreover, as northern Slovakia is a popular tourist 
destination, we cannot exclude the infection of the 
three patients in highly endemic localities.
Humans are considered to be unsuitable hosts for 
E. multilocularis [26]. Therefore, it is assumed that 
repeated or long-term exposure to contaminated envi-
ronment is needed to establish the infection [27]. In 
addition, the long incubation period (five to 15 years) 
contributes to the fact that alveolar echinococcosis 
is mainly diagnosed in older patients. The mean age 
of patients with alveolar echinococcosis in Slovakia 
was 52.3 years, but remarkable is the occurrence of 
alveolar echinococcosis in three persons younger than 
20 years. Two of them came from the Prešov Region 
and one lived in the Žilina Region. All three patients 
had severe organ damage indicating their exposure 
to E. multilocularis in early childhood. The mean age 
of patients reported to the European Echinococcosis 
Registry between 1982 and 2000 was 52.5 years, but 
only 2.1% of 559 persons were younger than 20 years 
[27]. Similarly, 2.1% and 5.2% of patients with affirmed 
alveolar echinococcosis in the highly endemic Ningxia 
Hui Region of China were younger than 20 years and 
30 years, respectively [28]. On the other hand, rela-
tively high occurrence of the disease in children was 
recorded in Poland, a country neighbouring Slovakia, 
where among 121 human cases, four (3.3%) were 
between the ages of six and 11 years, and the mean age 
of patients with alveolar echinococcosis was only 47.6 
years [29]. In Poland, E. multilocularis in red foxes was 
detected for the first time in 1995 [30] and one of the 
endemic localities, the Subcarpathian Province, is situ-
ated in the south of the country and borders with the 
highly endemic Žilina and Prešov Regions of Slovakia. 
Although the reason for increased incidence of alveolar 
echinococcosis in young people recorded in this study 
is unknown, we speculated that the environment of 
northern Slovakia is highly contaminated with infective 
stages of E. multilocularis.
The short interval between the first detection of 
E. multilocularis in foxes and the first human case (with 
severe organ damage) suggests that the parasite was 
present in Slovakia before 1999. Since then, increased 
awareness of public health authorities and physicians 
the possibility of serological examination of serum 
samples and new diagnostic methods, together with a 
constant high prevalence of the parasite in red foxes 
and increased density of the fox population, has con-
tributed to an increase in the number of human cases 
detected, especially since 2010.
We can assume that the real number of human alveolar 
echinococcosis may be several time higher than that 
shown by official data. A similar situation was recorded 
Table 3
Age of first diagnosis of alveolar echinococcosis, Slovakia, 
2000–2012 (n=26)
Age category Number of cases Incidence/100,000 inhabitantsa
<10 years 1 0.18
10–19 years 2 0.31
20–29 years 1 0.12
30–39 years 4 0.45
40–49 years 0 0.00
50–59 years 5 0.65
60–69 years 7 1.40
>70 years 6 1.33
a According to number of inhabitants in 2010 [36].
Figure 3
Confirmed human cases of alveolar echinococcosis, 
Slovakia, 2000–2013 (n=26)
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also in other countries; Jorgensen et al., for example, 
estimate that the incidence of the infection in Germany 
is three times higher than national surveillance data 
[31]. In Slovakia, confirmed cases of echinococcosis are 
reportable to the Regional Authorities of Public Health 
(RAPH) operated under Ministry of Health, and thereaf-
ter, the data are sent to the Epidemiological Information 
System (EPIS) or reported directly to the EPIS. Such a 
reporting system has some limitations since reports to 
EPIS come only from physicians and pathologists reg-
istered in the system. On the other hand, reports to 
the RAPH come from microbiological or parasitological 
laboratories. Due to the fact that each party relies on 
the other to report diagnosed cases, many cases can 
be neglected and the incidence can thus be seriously 
underestimated. Moreover, in many cases the diag-
nosis is established only as echinococcosis, and the 
aetiological agent of the disease, E. multilocularis or E. 
granulosus, is not determined. Similarly, the European 
Food Safety Authority (EFSA) supposes that current 
data about the occurrence of human echinococcosis in 
Member States of the European Union do not provide 
an accurate picture of the epidemiological situation. 
In 2010, approximately 22% of human cases remained 
undetermined [32]. Distinction between infections with 
E. granulosus and E. multilocularis would be beneficial 
because the two diseases require different manage-
ment of prevention and treatment [32].
Despite the fact that alveolar echinococcosis was dis-
covered in Slovakia already 13 years ago and despite (or 
maybe because of) the popularisation of this medical 
problem, public knowledge on its epidemiology is still 
greatly misleading. In Slovakia, as in other European 
countries, biased information about eating berries and 
mushrooms as the most important infection risk factor 
is often promoted in media, while little consideration 
is given to ownership of dogs and contact with wild 
carnivores. Nevertheless, several case–control stud-
ies aimed at investigating the epidemiology of alveo-
lar echinococcosis have affirmed ownership of dogs 
and contact with carnivores as the most important risk 
factors [22,23,33]. Therefore, regular deworming treat-
ment of dogs could be an effective preventive meas-
ure. In contrast, two studies from 2004 and 2005 did 
not find an association of alveolar echinococcosis with 
picking and eating berries and mushrooms from fields 
and forests [23,34].
The above facts draw attention to the need to revise 
the existing reporting system, improve the national 
surveillance system and engage specialists outside the 
medical community (public health professionals, para-
sitologists, veterinarians, zoologists and ecologists) 
for effective management of prevention and control 
strategies. Knowledge on how to minimise the risk of 
E. multilocularis transmission is not yet established in 
new endemic areas.  Eradication of the parasite from 
the environment by means of long-term baiting cam-
paigns in the fox population appears to be an effective 
tool, but has never been completely successful [35,36]. 
The baiting programmes depend strongly on sev-
eral factors, mainly on available financial resources. 
Therefore the prevention of human alveolar echinococ-
cosis should be based on integrated control measures 
such as increasing public awareness of hygienic meas-
ures, regular anthelmintic treatment of domestic carni-
vores or vole habitat management [36].
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Lyme borreliosis (LB) has become a major concern 
recently, as trends in several epidemiological stud-
ies indicate that there has been an increase in this 
disease in Europe and America over the last decade. 
This work provides estimates of LB incidence and 
hospitalisation rates in France. LB data was obtained 
from the Sentinelles general practitioner surveillance 
network (2009–2012) and from the Programme de 
Médicalisation des Systèmes d’Information (PMSI) 
data processing centre for hospital discharges (2004–
09). The yearly LB incidence rate averaged 42 per 
100,000 inhabitants (95% confidence interval (CI): 
37–48), ranging from 0 to 184 per 100,000 depend-
ing on the region. The annual hospitalisation rate due 
to LB averaged 1.55 per 100,000 inhabitants (95% CI: 
1.42–1.70). Both rates peaked during the summer and 
fall and had a bimodal age distribution (5–10 years 
and 50–70 years). Healthcare providers should con-
tinue to invest attention to prompt recognition and 
early therapy for LB, whereas public health strategies 
should keep promoting use of repellent, daily checks 
for ticks and their prompt removal.  
Introduction
Lyme borreliosis (LB) is the most common vector-borne 
disease in the northern hemisphere [1-3]. The eco-
nomic and social costs of managing the disease repre-
sent an important burden on both health services and 
society [4,5]. Several epidemiological studies describe 
a 2 to 3.6-fold increase in the incidence of this disease 
over the last decade, in Europe as well as in the United 
States (US) [6-9].
The American surveillance system, based on notifica-
tions of observed cases, has been active since 1991. 
In Europe, most countries do not have national moni-
toring data at their disposal. The Czech Republic and 
Slovenia are among the few exceptions [1]. In France, 
the only existing nationwide study is a prospective 
study conducted by the Sentinelles network with gen-
eral practitioners (GPs) from 1999 to 2000. It esti-
mated the incidence of the disease at 9.4 per 100,000, 
with important inter-regional variations [10]. Several 
regional studies were also conducted, some on high-
risk populations (forest workers), others on the gen-
eral population in high-risk regions. In eastern France, 
disease incidence was estimated at 200 per 100,000 
inhabitants, and at over 500 per 100,000 in certain 
areas [11,12].
Estimates of the epidemiological characteristics of LB 
are useful to orient control and prevention measures, 
as well as to assess their effectiveness. These data 
are also necessary to elaborate factual risk commu-
nication messages provided to the lay public or the 
media. Since 1984, the Sentinelles network collects, 
processes, forecasts and dispatches epidemiological 
data on the activity of GPs in France [13], in real time. In 
2009, LB was added to the list of the monitored health 
indicators.
We analysed the data collected by the Sentinelles 
network over the first four years of LB surveillance in 
France (2009–2012). We also analysed the national 
hospitalisation databases from 2004 to 2009 (the lat-
est available data at the time of writing this paper).
Methods
Incidence and characteristics of Lyme 
borreliosis cases (2009–2012)
The Sentinelles network GPs notify weekly the cases 
of LB they identify during consultations to the net-
work’s electronic information system. Notifications 
are made online throughout the year, in a standard-
ised way. Sentinelles GPs make up a representative 
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sample of the national GPs, both in terms of practice 
area and age distribution of their patients [14]. To be 
reported by GPs, cases had to meet the following defi-
nitions as stated in the European Concerted Action on 
Lyme Borreliosis criteria: (i) presence of an erythema 
migrans (clinical diagnosis); or (ii) appearance of neu-
rological, articular (arthritis only), cutaneous or cardiac 
symptoms evocative of Lyme disease, in a patient with 
positive serology [15].
For each notified case, a standardised questionnaire 
provided information on the patient’s age and sex, 
the date of diagnosis, a history of tick bite before the 
consultation (date of bite), presence of asthenia, myal-
gia, cutaneous manifestations (erythema migrans 
with a single or numerous lesion(s), lymphocytoma, 
acrodermatitis (ACA)), neurological manifestations 
(meningoradiculitis, clinical signs of meningitis, menin-
goencephalitis, radiculitis, facial paralysis, events 
related to another cranial nerve), the presence of arthri-
tis (articulation(s) concerned) or cardiac events (atrio-
ventricular block, pericarditis, myocarditis, other) and, 
when available, the results of cerebrospinal fluid (CSF) 
analysis and serological tests. Three of the authors 
(AV, CA, TH) validated the reported cases when they 
met the adopted case definition. Validation of cases 
is an ongoing regular activity of the surveillance pro-
cedure and involves checking the consistency of data 
reported in the standardised questionnaire for each 
reported cases. When needed, GPs are contacted for 
more information. Cases of meningoradiculitis or uni-
lateral facial paralysis were validated even if CSF fluid 
analysis had not been done, when they were clinically 
very suggestive (consensus agreement between three 
authors, AV, CA and TH) in patients who reported a his-
tory of erythema migrans less than two months before 
the onset of neurological manifestations [16].
Cases reported from 1 January 2009 through 31 
December 2012 were analysed. The annual incidence 
rate was calculated as follows: the average number of 
cases notified by Sentinelles GPs (adjusted for partici-
pation and geographic distribution) was multiplied by 
the total number of private GPs practicing in France 
[17]. This product was then divided by the French popu-
lation [18]. Confidence intervals were estimated under 
the assumption that the number of reported cases fol-
lowed a Poisson distribution.
Lyme borreliosis hospitalisations (2004–2009)
Hospitalisation data were collected by reviewing all 
hospital discharge reports containing an LB code from 
1 January 2004 through 31 December 2009 (the latest 
available data at the time of writing this paper), all 
obtained through the Programme de Médicalisation 
des Systèmes d’Information (PMSI) data processing 
centre [19]. This database is a national register of all 
discharges from all short-stay/acute-care hospitals. It 
collects data described by the physicians who took care 
of the patients during their hospitalisation, using the 
International Classification of Diseases, 10th revision 
(ICD-10) [20]. We identified all the hospitalisation 
reports for which a LB code was reported, i.e. M01.2* 
(Lyme arthritis), L90.4 (acrodermatitis) or A69.2 (Lyme 
disease), either for primary or secondary diagnoses. A 
hospitalisation was considered compatible with LB and 
retained in the analyses when the data in the hospital 
discharge report satisfied one of the following criteria 
(Table): (i) a hospital discharge report with a code spe-
cific for LB diagnosis (ICD-10 codes M01.2* or L90.4), 
(ii) a hospital discharge report with ICD-10 Code A69.2 
in the absence of any other diagnosis, or (iii) a hospital 
discharge report with ICD-10 Code A69.2 together with 
one or more associated diagnosis code(s) compatible 
with LB symptoms (neurological, cardiac, articular and 
ocular disorders). Hospitalisations were described by 
age, sex, region of residence of the patient, and types 
of disorders. Also, seasonality and the mean dura-
tion of hospitalisation were presented. To estimate 
the average annual incidence rate of hospitalisations 
(national and regional), the number of hospital stays in 
a given geographical area was divided by the average 
population in the study period, and then multiplied by 
100,000 [18].
Results
Incidence and characteristics of Lyme 
borreliosis cases (2009–2012)
From 2009 through 2012, GPs of the Sentinelles net-
work reported 441 cases of Lyme borreliosis, 110 of 
which were not chosen for validation because they did 
not meet the criteria. These were mostly late manifes-
tations without serological confirmation (n=42), tick 
bites without any clinical event (n=25), insufficiently 
completed questionnaires (n=19), positive serology 
without any associated clinical event (n=8), diagnosis 
errors later confirmed by the GP (n=7), data capture 
errors (n=4), prevalent but non incident cases (n=5). 
The remaining 331 cases were validated and analysed.
The estimated yearly LB incidence averaged 26,584 
cases (95% confidence interval (CI): 23,053–30,115), 
representing an estimated average incidence rate of 42 
per 100,000 national population (95% CI: 37–48). This 
result was stable over the four years of monitoring: 42 
per 100,000 inhabitants (95% CI: 30–54) in 2009, 42 
per 100,000 (95% CI: 32–52) in 2010, 41 per 100,000 
(95% CI: 31–51) in 2011 and 44 per 100 000 (95% CI: 
32–56) in 2012. Regionally, the average incidence rate 
ranged from 184 (95% CI: 31–356) per 100,000 popula-
tion in the Limousin region and 157 (95% CI: 34–279) 
in Alsace to 0 in Nord-Pas-de-Calais and Bourgogne 
(Figure 1A). The incidence peaked during the months of 
June to October (Figure 2A).
Women represented 52% of these 331 cases (p=0.37). 
The age distribution revealed two peaks, between 5 
and 10 years and between 50 and 70 years (Figure 3). A 
tick bite was reported by 74% of patients. The average 
delay between the bite and the date of diagnosis was 
28 days, with a median of 10 days. Most reported cases 
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had erythema migrans (93.6%), with a single lesion in 
91% of cases and multiple lesions in 9% of cases. Other 
clinical forms of the disease were reported in a limited 
number of cases: cutaneous lymphocytoma (n=4), ACA 
(n=3), arthritis (n=9), neurological disorders (n=5), and 
one patient presented both arthritis and neurological 
disorders. For one patient only presenting a neurologi-
cal form of LB, a lumbar puncture was performed to 
confirm the diagnosis.
Lyme borreliosis hospitalisations (2004–2009)
Among the 14,348 files extracted in France from the 
PMSI from 2004 through 2009, 5,727 were consid-
ered compatible with a diagnosis of Lyme disease, i.e. 
40% of all hospitalisation records with an LB code. 
Therefore, the estimated average incidence of hospital-
isations was 954 per year (Figure 4), which represents 
an estimated annual average hospitalisation rate over 
the period of 1.55 per 100,000 inhabitants (95% CI: 
1.42–1.70), ranging from 1.38 to 1.87. Regional varia-
tions of hospitalisation rates were remarkable, ranging 
from 6.72 per 100,000 inhabitants per year in Alsace, 
to 0.30 in Corsica (Figure 1B).
These hospitalisations concerned women in 42.2% 
of cases (p<0.001). The age distribution revealed two 
peaks: one between 5 and 10 years and another around 
the age of 55 years (Figure 5). Reasons for hospitalisa-
tion were neurological disorders (n=2,820), LB with no 
associated diagnosis (n=1,860), arthritis (n=660), car-
diac events (n=304), ocular disorders (n=87) and ACA 
(n=85). The monthly distribution of hospitalisations 
(month of entry) peaked between June and November 
(Figure 2B). The average duration of stay was 5.3 days 
Table 1
ICD-10 codes of clinical disorders that may be related to Lyme borreliosis
ICD-10 chapters and group of conditions concerneda ICD-10 code concerned
Chapter VI: Diseases of the nervous system 
Inflammatory diseases of the central nervous system G00-9
Disorders of the trigeminal nerve G50.8, G50.9
Facial nerve disorders G51, G51.0, G51.8, G51.9
Disorders of other cranial nerves G52, G52.0-3, G52.7-9
Cranial nerve disorders in diseases classified elsewhere G53, G531, G538
Nerve root and plexus disorders G54, G54.0-5, G54.8-9
Other polyneuropathies G62, G62.8-9
Polyneuropathy in diseases classified elsewhere G63, G63.0
Other disorders of the peripheral nervous system G64
Chapter VII: Diseases of the eye and adnexa  
Iridocyclitis   H20, H20.0-1, H20.8-9
Other disorders of iris and ciliary body  H21, H21.8-9
Disorders of iris and ciliary body in diseases classified elsewhere  H22, H22.0-1, H022.8
Chorioretinal inflammation  H30, H30.0-9
Other disorders of the choroid H31, H31.8-9
Chorioretinal disorders in diseases classified elsewhere  H32, H32.0-8
Chapter IX: Diseases of the circulatory system
Acute pericarditis  I30, I30.0-9
Pericarditis in diseases classified elsewhere  I32, I32.0-8
Acute myocarditis  I40, I40.0-9
Myocarditis in diseases classified elsewhere  I41, I41.0, I41.2, I41.8
Cardiomyopathy  I42, I42.9
Cardiomyopathy in diseases classified elsewhere I43, I43.0
Atrioventricular and left bundle branch block  I44, I44.0-7
Other conduction disorders  I45, I45.0-9
Other heart disorders in diseases classified elsewhere  I52, I52.0-8
Chapter XIII: Diseases of the musculoskeletal system and connective tissue
Arthritis and polyarthritis due to other specified bacterial agents  M00.8, M00.80-9
Direct infections of joint in infectious and parasitic diseases classified elsewhere M01, M01.2, M01.20-9, M01.30-9, M01.80-9
Other arthritis  M130-9
Arthropathies in other diseases classified elsewhere  M14, M14.8
a International Classification of Diseases, 10th Revision [20].
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and varied, according to the LB form, from an average 
of 3.0 days for hospitalisations coded with an iso-
lated LB code, to 8.3 days for LB associated to cardiac 
disorders.
Discussion
Data from the Sentinelles GP network and administra-
tive hospitalisation database allowed for an updated 
and ongoing description of the epidemiology of LB in 
France. Although they covered different time periods, 
there was consistency between the data sources in 
regard to age distribution, seasonality and spatial dis-
tribution. The study confirmed that the incidence was 
greater in the eastern and central regions of France, 
increased in summer, and was higher among young 
children and older adults. It also confirmed that GPs 
play a major role in diagnosing and treating the early 
forms of the infection. Even though they were unusual, 
severe forms made hospitalisation necessary.
On the basis of the 331 cases collected and validated 
by the Sentinelles network, the LB incidence was esti-
mated at 42 (95% CI: 37–48) for 100,000 inhabitants. 
The actual LB incidence could in fact be higher than 
this estimate, since patients who did not consult a GP 
were not covered by this study. There is no published 
or unpublished information that could help assess the 
magnitude of this effect. However, nowadays in France, 
people cannot go directly to a specialist without first 
consulting a GP. It is therefore likely that the vast major-
ity of patients had been seen by a GP. The incidence 
rates estimated here can be compared with incidence 
rates in other European countries, although such com-
parisons must be interpreted with caution. Indeed, 
there are differences between countries in the process 
of data collection. Only some countries use a continu-
ous surveillance system, and case definitions and lab-
oratory confirmation methods vary [1,9]. In 2005, the 
highest incidence rates of LB in Europe were reported 
in Slovenia with 206 cases per 100,000 inhabitants, 
Austria with 135 cases per 100,000 inhabitants and the 
Netherlands with 103 cases per 100,000 inhabitants 
[9]. A high yearly incidence rate of LB (131 per 100,000 
inhabitants) was also reported in Switzerland between 
2008 and 2011 [21]. Incidence measured in Germany 
in 2006 amounted to 37.3 per 100,000 inhabitants in 
six of the 16 federal states [8]. In the Czech Republic 
in 2006, it was 42.6 per 100,000, close to the national 
incidence in France. In Belgium, it was 16 per 100,000 
in 2005 [9], whereas the Belgian network of sentinel 
GP estimated the incidence rate of erythema migrans 
at 90.2 per 100,000 in 2009 [22]. The incidence rate 
was below 1 per 100,000 in Italy and Portugal in 2005 
[9].
The only earlier available data on French national inci-
dence of LB were provided by a study conducted by the 
Sentinelles network in 1999 and 2000. It estimated the 
national incidence rate at 9.4 per 100,000 inhabitants 
[10]. The higher incidence reported in the present study 
could suggest that the LB incidence rate has increased 
in France. However, these incidences must be compared 
with caution, since different artifacts may have contrib-
uted to the higher numbers. Firstly, it has been shown 
Figure 1
Estimated annual regional incidence rates of Lyme borreliosis in general practice (2009–2012) and hospitalisations (2004–
2012), France
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that the incidence of LB is highly sensitive to changes 
in surveillance methods [23]. Indeed, the methodol-
ogy used by Letrilliart et al. in 1999–2000 was differ-
ent from the one we applied, and probably led to an 
underestimation of the incidence rate in their study. 
At the time, data were not collected through a routine 
systematic and standardised surveillance, as they 
have been since 2009. The routine surveillance of the 
Sentinelles network is based on periodic reports from 
sentinel physicians (usually weekly reports). Thus, if a 
physician does not provide report for several weeks, 
they will not be counted as a participating during 
those weeks. In the 1999 survey, it was assumed that 
physicians reported cases actively during the entire 
study period. Thus, compared to routine surveillance, 
the number of cases declared in the 1999 study was 
attributed to an overestimated number of participating 
GPs, resulting in lower incidence estimates. Secondly, 
LB today is better known to the public and the GPs 
than it was in 1999, which may have contributed to the 
strong increase in estimated LB incidence we report 
here [6]. Finally, the number of hospitalised cases was 
stable over the period 2004–2009 and seems incom-
patible with a four-fold increase in incidence suggested 
by a comparison of incidence estimates derived from 
the 1999–2000 study and the 2009–12 surveillance 
data. The hospital discharge database being a stable 
system, surveillance bias is unlikely, and the database 
can therefore provide useful data for trend analyses.
Nevertheless, numerous studies and surveillance data 
from other European countries and the US showed 
Figure 2
Mean monthly incidence rate of Lyme borreliosis in general practice (2009–2012) and number of hospital admissions 
(2004–2009), France)
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that the LB incidence may indeed have increased over 
the past few decades. In the US, a continued surveil-
lance system was created in 1991, and the incidence 
has increased by 101% since then [6]. In Europe, an 
increase in LB was observed in several countries [9]. 
Between 1990 and 2001, the incidence rate in the 
Czech Republic doubled [1]). In Germany, Fulop et al. 
describe a 110% increase between 2001 and 2006 [8]. 
In the United Kingdom, case numbers have increased 
3.6-fold between 2001 and 2011 [24]. In addition, some 
factors not related to surveillance artifacts may have 
contributed to an actual incidence increase, such as 
climate changes [25,26], increases in the population 
of wild animals hosting ticks, modifications in agricul-
tural and forest landscapes that can lead to a higher 
density of tick populations [1], or reduction in biodiver-
sity that can increase the prevalence of ticks carrying 
Borellia [27].
Regional incidence rates varied considerably in France, 
from 0 per 100,000 inhabitants to 184 per 100,000. 
These variations could be explained by participa-
tion biases. However, they were the same as those 
observed in the earlier Sentinelles network study [10] 
and, more importantly, the regional hospitalisation 
incidences corroborated the GP surveillance data, as 
shown by the similar distribution of GP and hospitali-
sation data in Figure 1. Other published studies con-
firmed the regional distribution reported here [11]. 
In the US, incidence also varied among states, from 
less than 0.01 per 100,000 inhabitants in Montana or 
Colorado, to 73 per 100,000 in Connecticut [6]. The 
confirmation of interregional variations is an asset to 
guide future studies and develop more efficient public 
health actions.
In 94% of the cases in France, the infection was diag-
nosed at the erythema migrans stage. In the US, the 
proportion of erythema migrans was lower, estimated 
at 69% [6]. However, the data collection process in 
the US included cases reported through laboratory-
based surveillance that are more likely to have late 
manifestations of LB [23]. An earlier study conducted 
in France with GPs, specialists and hospital practi-
tioners reported a proportion of erythema migrans of 
68% [11]. In Europe, published data varied from 65% 
to 95% [11,28,29]. These observations suggest that 
either the incidence of late Lyme disease forms in gen-
eral practice in France is underestimated or the inci-
dence of erythema migrans is overdiagnosed. Indeed, 
the lesion can be confused with other dermatological 
disorders, and the positive predictive value of an ery-
thema migrans diagnosis made by GPs in France has 
been estimated at 72% [30].
There was a marked difference in the sex ratio between 
outpatients (predominantly female) and inpatients 
(predominantly male), for which we have no expla-
nation. Sex differences in the risk of contracting tick 
bites, incidence rates, and clinical picture of erythema 
migrans have been reported, although the biological, 
immunological, and sociological mechanisms causing 
these differences have not been determined [31].
There are limits to the use of data coming from the 
national hospitalisation statistics, including diagnosis 
and coding mistakes, unintentional omissions, partial 
reporting of pre-existing conditions, lack of informa-
tion about treatments (whether or not patients received 
an LB-effective antibiotic could help validate the diag-
nosis), the frequent unavailability of medical history 
forms to the certifying practitioner or difficulties in 
determining the initial cause of hospitalisation when 
several associated pathologies are involved. Indeed, it 
is possible that the recorded diagnoses were given by 
physicians who did not base their decision on accepted 
case definitions. Also, the diseases defined by the 
ICD-10 codes that we used are not specific for LB, their 
aetiologies may be numerous and in many cases idi-
opathic. It has been previously shown that the positive 
Figure 3
Annual incidence rates of Lyme borreliosis by age group 
as estimated by the general practitioners’ Sentinelles 
network, France, 2009–2012
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predictive value of the LB code in the PMSI database 
was 65% [32]. We therefore considered it necessary to 
set up a selection process for the reported hospitalisa-
tions. In the end, we only kept 40% of the registered 
reports. Nevertheless, the predictive value of our case 
definition could remain low due to the lack of specific-
ity of the retained hospitalisation definitions (related 
to the complexity of databases such as the PMSI hos-
pitalisation database). Therefore, our study could also 
overestimate the hospitalisation rates for LB in France. 
However, the PMSI database proved a useful tool to 
monitor trends over time, determine the seasonality, 
determine high-risk regions, and provide details on 
characteristics of hospitalised patients.
Conclusions
In conclusion, a countrywide sentinel network and 
hospitalisation statistics produced epidemiological 
data that were sustainable and consistent over time 
and space. They were suitable for following trends 
and estimating the burden of this disease for which 
there is significant public concern. Determination of 
the healthcare burden associated with LB can inform 
public health policy and enable valid analysis of the 
efficiency of LB control measures. Furthermore, we 
believe that this study could help elaborate factual 
risk communication messages provided to the lay pub-
lic or the media. Healthcare providers should continue 
to invest attention into prompt recognition and early, 
appropriate therapy for LB. Also, public health strate-
gies should keep promoting the use of repellent, daily 
checks for ticks and their prompt removal, mainly in 
the age groups, in the regions and during the months 
with the highest incidences.
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This study reports the first vaccine effectiveness 
(VE) estimates for the prevention of general practice 
visits and hospitalisations for laboratory-confirmed 
influenza from an urban population in Auckland, New 
Zealand, in the same influenza season (2013). A case 
test-negative design was used to estimate propensity-
adjusted VE in both hospital and community settings. 
Patients with a severe acute respiratory infection 
(SARI) or influenza-like illness (ILI) were defined as 
requiring hospitalisation (SARI) or attending a gen-
eral practice (ILI) with a history of fever or measured 
temperature ≥38 °C, cough and onset within the past 
10 days. Those who tested positive for influenza virus 
were cases while those who tested negative were con-
trols. Results were analysed to 7 days post symptom 
onset and adjusted for the propensity to be vaccinated 
and the timing during the influenza season. Influenza 
vaccination provided 52% (95% CI: 32 to 66) protec-
tion against laboratory-confirmed influenza hospitali-
sation and 56% (95% CI: 34 to 70) against presenting 
to general practice with influenza. VE estimates were 
similar for all types and subtypes. This study found 
moderate effectiveness of influenza vaccine against 
medically attended and hospitalised influenza in New 
Zealand, a temperate, southern hemisphere country 
during the 2013 winter season. 
Introduction
Influenza infection causes a major burden of illness in 
adults and children [1,2]. Seasonal trivalent influenza 
vaccines (TIVs) are effective in preventing a range of 
laboratory-confirmed outcomes [3], but effectiveness 
varies by severity and season, the presence of comor-
bidities and age [4,5].
The SHIVERS (Southern Hemisphere Influenza Vaccine 
Effectiveness, Research and Surveillance) study has 
allowed estimation of vaccine effectiveness (VE) 
against influenza illness requiring hospitalisation 
since 2012 and against influenza illness requiring pri-
mary care (general practice) since 2013.
In New Zealand, seasonal non-adjuvanted inactivated 
trivalent influenza vaccine is available annually free 
of charge to all adults aged 65 years and over, preg-
nant women and all those over six months of age 
with chronic medical conditions that are likely to 
increase the severity of the infection. Influenza vac-
cines are also available on the private market for all 
others over six months of age. Two commercial vac-
cine products were available in the New Zealand 
market in 2013: Fluarix (GlaxoSmithKline) and Fluvax 
(bioCSL). Both vaccines contained A/California/7/2009 
(H1N1)-like virus, A/Victoria/36/2011 (H3N2)-like virus 
and B/Wisconsin/1/2010-like virus (belonging to B/
Yamagata/16/88 lineage).
Using the case test-negative design, we estimated 
the effectiveness of seasonal trivalent inactivated 
influenza vaccine in preventing laboratory-confirmed 
influenza in patients hospitalised with severe acute 
respiratory infections (SARI) and in patients presenting 
to general practice with an influenza-like illness (ILI) 
during the 2013 influenza season, which is from March 
to September in New Zealand.
Methods
Ethics approval for the study was obtained from the 
Northern A Health and Disability Ethics Committee 
(NTX/11/11/102 AM02).
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Study design
In both hospital and community settings, we conducted 
a study using a standard case test-negative design 
[6], drawing on an urban population of approximately 
838,000 people in Central, South and East Auckland 
[7].
For community cases, we recruited 18 sentinel general 
practices with 103,884 enrolled patients. Patients in 
these sentinel practices were broadly representative of 
the ethnically diverse urban population of Auckland by 
age and sex distribution, but with more Pacific people 
(27% in the practices compared with 15% in the source 
population) and slightly fewer people of Asian descent 
(14% versus 19%, respectively)[7].
The practices recruited individuals aged six months 
and older who presented to a general practitioner or 
practice nurse with ILI, defined as a history of fever or 
measured fever of ≥38 °C and cough, with onset during 
the preceding 10 days [8,9].
All patients presenting to one of the sentinel general 
practices with suspected respiratory infections were 
screened by the general practitioner or nurse for ILI. All 
identified ILI cases were entered on an electronic form 
in the practice management system and a nasopharyn-
geal or throat swab was collected for influenza virus 
testing from all consenting patients.
For hospitalised patients, we enrolled individuals aged 
six months and older who were admitted with SARI to 
one of the four public hospitals covering the whole 
population in this catchment area. On the basis of the 
World Health Organization (WHO) definition, SARI was 
defined as hospitalisation with a patient-reported his-
tory of a fever or a measured temperature of ≥38 °C and 
cough with onset within the past 10 days [10]. A con-
firmed case of influenza was defined as a SARI or ILI 
patient with a positive laboratory result for any influ-
enza virus detected by real-time reverse transcription 
polymerase chain reaction (RT-PCR), while non-cases 
(controls) were patients with SARI or ILI who tested 
negative for all influenza viruses.
SARI patients were identified following screening of 
patients admitted with respiratory disease by dedi-
cated research nurses. Overnight admissions of 
patients with respiratory symptoms were screened by 
the nurses on the following day. All patients satisfying 
the SARI case definition were invited to participate in 
the study. Patients who gave verbal consent completed 
a case report form and provided a nasopharyngeal 
swab or aspirate for influenza virus testing.
Patients who were identified at seven days post onset 
of symptoms were excluded from the ILI and SARI anal-
ysis, based on the pattern of shedding, which peaks in 
Figure 1
Study participants with influenza-like illness who were influenza positive or negative by week, New Zealand, 2013 influenza 
season 
ILI: influenza-like illness. 
Weeks 18 to 52 are shown (29 April to 31 December 2013).
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the first three days, then declines steadily until days 
7–9 [9]. We also excluded patients with incomplete 
data for vaccination status or age, all infants under 6 
months of age, children aged under 9 years who were 
only given one dose of trivalent inactivated influenza 
vaccine, patients who were vaccinated less than 14 
days before admission to hospital or presentation to 
general practice. For patients with multiple episodes, 
the first influenza virus-positive episode was used for 
the analysis, or the first illness episode if there was no 
influenza virus-positive episode.
The influenza season was defined as starting when 
there were two consecutive weeks with two or more 
cases and ending when there were no consecutive 
weeks with two or more cases. Analysis was thus 
undertaken from 3 June to 10 November 2013 for SARI 
cases and from 13 May to 27 October 2013 for ILI cases 
(Figures 1 and 2).
Participant information
For all ILI patients, variables extracted from the elec-
tronic form and patient management system included 
age, sex, ethnicity, chronic medical conditions and 
current smoking status, socio-economic status as 
identified by the New Zealand deprivation status (a 
meshblock measure reflecting eight dimensions of dep-
rivation distributed into deciles) [11] and a subjective 
assessment of obesity by the clinician as body mass 
index measurements were not consistently available.
Similar information was collected for all SARI patients, 
but for this group we also collected the following: a 
patient- or caregiver-reported measure of depend-
ence (which assessed requirement for assistance with 
normal activity or full dependency on nursing care); 
a measure based on long-term use of oxygen that we 
labelled ‘frailty’; a history of chronic medical condi-
tions; and a self-defined, standardised functional well-
being health status score from a national survey [12], 
combining fair or poor well-being versus all other more 
positive well-being scores.
In New Zealand, almost all influenza vaccinations are 
administered in general practices. For ILI cases, vac-
cination status was taken from the general practice 
record. SARI vaccination status for the 12 months 
before hospitalisation was determined by self-report.
Laboratory methods
Nasopharyngeal swabs, aspirates and other respira-
tory samples were collected according to hospital or 
general practice standard procedures. Samples were 
tested using the United States Centers for Disease 
Control and Prevention (CDC) real time RT-PCR proto-
col [13] or the AusDiagnostic PCR protocol [14]. The 
AusDiagnostic assay had a sensitivity of 100% and 
Figure 2
Study participants with severe acute respiratory infections who were influenza virus positive and negative by week, New 
Zealand, 2013 influenza season
SARI: severe acute respiratory infection.
Weeks 18 to 52 are shown (20 April to 31 December 2014).
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specificity of 96.6% when the United States CDC 
method was used as the comparator [15]. RT-PCR 
assays detected influenza virus types A and B and sub-
typing was performed for type A. All influenza virus 
PCR-positive samples were forwarded to the National 
Influenza Centre and characterised antigenically using 
established methods [14].
Statistical analysis
Univariate chi-squared tests were used to compare 
characteristics of patients who were influenza virus 
positive (cases) and negative (controls). A multivari-
ate logistic model restricted to the test-negative con-
trols was used to calculate an adjusted odds ratio for 
the propensity to be vaccinated for a range of patient 
characteristics possibly associated with vaccination 
(Table 1) and used in a previous study [16]. The results 
from this propensity model are presented as odds 
ratios. This propensity model was then applied to the 
complete dataset to generate individual propensity 
scores for vaccination. In order to ensure these pro-
pensity scores were linear with respect to influenza 
virus positive status, we used the cubic spline for 
these scores as an adjustment variable for estimating 
VE. For both SARI and ILI, we calculated the crude VE, 
adjusting only for the timing of presentation relative 
to the influenza season (defined as weeks from the 
peak), and the adjusted VE, which included the timing 
of presentation and the cubic spline of the fitted values 
of the propensity model. VE estimates were calculated 
against both SARI and ILI, by influenza virus type and 
subtype and by age group (6 months–17 years, 18–64 
years and ≥65 years).
For all patient characteristics, other than age and vac-
cination status, each missing data point was imputed 
as the baseline (referent) value for the corresponding 
variable. The baseline values were: non-Māori, non-
Pacific ethnicity, female, not  in New Zealand depri-
vation groups 8,9 or 10 (the three lowest deprivation 
deciles), not pregnant, current non-smoker, without 
chronic disease, not obese, with self-rated health aver-
age or better, not using long-term oxygen and living 
without assistance). All male patients and all female 
Table 1
Characteristics of study participants with influenza-like illness  and severe acute respiratory infection, New Zealand, 2013 
influenza season
Characteristic
Hospitalised with 
severe acute respiratory infection
General practice visit for 
influenza-like illness
Cases
n (%)a
Cases
n (%)a
Cases
n (%)a
Cases
n (%)a
Vaccinated 82 (36.6) 372 (45.4) 44 (9.1) 177 (17.4)
Median age in years 49 (21.9) 41 (5.0) 25 (5.2) 21 (2.1)
Male 105 (46.9) 410 (50.1) 224 (46.5) 415 (41.0)
Age group 
6 months–5 years 40 (17.9) 271 (33.1) 74 (15.4) 255 (25.2)
6–17 years 11 (4.9) 35 (4.3) 141 (29.3) 221 (21.8)
18–45 years 51 (22.8) 129 (15.8) 173 (35.9) 330 (32.6)
46–64 years 51 (22.8) 156 (19.1) 75 (15.6) 159 (15.7)
65–79 years 47 (21.0) 134 (16.4) 16 (3.3) 41 (4.0)
≥80 years 24 (10.7) 93 (11.4) 3 (0.6) 7 (0.7)
Ethnicity
Māori 29 (12.9) 169 (20.7) 18 (3.7) 57 (5.6)
Pacific 77 (34.4) 238 (29.1) 97 (20.1) 203 (20.0)
Other characteristics
Mean New Zealand deprivation score b 5.3 5.9 4.95 4.9
Pregnant 5 (2.2) 5 (0.6) Not collected Not collected
Current smoker 24 (10.7) 86 (10.5) 30 (6.2) 56 (5.5)
Chronic disease 138 (61.6) 528 (64.5) Not collected Not collected
Obesec 44 (19.6) 134 (16.4) 17 (3.5) 42 (4.2)
Self-defined well-being health status of poor or faird 28 (12.5) 120 (14.7) Not collected Not collected
Frailtye 5 (2.2) 24 (2.9) Not collected Not collected
Dependencef 10 (4.5) 50 (6.1) Not collected Not collected
Total 224 (100) 818 (100) 482 (100) 1,013 (100)
a Unless otherwise indicated.
b A meshblock measure reflecting eight dimensions of deprivation distributed into deciles.
c Subjective assessment of obesity by the clinician.
d A self-defined, standardised functional well-being health status score.
e Defined as currently on long-term oxygen use.
f Requirement for assistance with normal activity or full dependency on nursing care, as reported by the patient or caregiver.
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patients not aged 13–55 years were assumed to be not 
pregnant. Overall, 53 SARI (5%) cases and 1 ILI (0.1%) 
case had any imputed covariates. Sensitivity analyses 
were performed using only those individuals with com-
plete data.
As a further sensitivity analysis, we also compared the 
overall VE estimate from the propensity-adjusted model 
with an epidemiological model that included covari-
ates that were assessed as potential confounders and/
or effect modifiers (Table 1) and a statistical model, 
derived from the epidemiological model, where only 
covariates that were significant at the 0.05 level were 
included in the final model.
Results
Characteristics and vaccination status of participants
ILI and SARI patients in this study by influenza virus 
status are shown in Figures 1 and 2.
Figure 3
Flowchart of all selected, recruited and tested patients with influenza-like illness and severe acute respiratory infection for 
influenza vaccine effectiveness analysis, New Zealand, 2013 influenza season
ILI: influenza-like illness; SARI: severe acute respiratory infection.
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A total of 1,042 SARI admissions and 1,495 ILI patients 
were included in the analysis, of whom 224 (21%) and 
482 (32%) were influenza virus positive, respectively. 
Of the 224 SARI admissions who tested influenza 
virus positive, 82 (37%) were vaccinated, compared 
with 372/818 (45%) who tested negative. Despite our 
attempts, we were unable to verify self-reported vac-
cination status of SARI patients with the vaccine 
providers.
Of the 482 ILI patients who tested influenza virus posi-
tive, 44 (9%) were vaccinated, compared with 177/1,013 
(17%) who tested negative (Figure 3). The proportion 
vaccinated did not change throughout the season. In 
those excluded because of incomplete laboratory tests, 
self-reported vaccination in the previous 12 months 
among SARI cases was 49/135 (36%), slightly less 
than the proportion of included SARI cases, 454/1,042 
(44%). In the ILI cases, the proportion vaccinated was 
much higher, at 8/21 (38%), in those excluded because 
of incomplete laboratory tests compared with the ILI 
cases included, of whom 9% (44/482) were vaccinated.
Influenza-positive cases and influenza-negative con-
trols were compared across a range of patient char-
acteristics. SARI and ILI patients who were aged 6 
months to 5 years or over 80 years, and those present-
ing outside the influenza season were less likely to test 
positive. In comparison with the community patients, 
the hospitalised patients were more likely to be vac-
cinated, to be older, to live in a deprived area, to be 
of Māori or Pacific ethnicity, to be a current smoker 
and to be obese (Table 1). Details on pregnancy were 
poorly recorded but less than 3%  (30/1,042) of other 
data fields were missing for both SARI and ILI patients.
Of the 706 influenza cases detected in both SARI and 
ILI patients, 453 (64%) were type A, 335 (47%) A(H3N2), 
43 (6%) A(H1N1) and 75 (11%) A not subtyped) and 258 
(37%) type B (107 B/Wisconsin/1/2010-like of the B/
Yamagata lineage, 2 (0.3%) B/Brisbane/60/2008-like 
of the B/Victoria lineage and 149 (21%) where the B 
lineage was not determined). Five cases (0.7%) tested 
positive for both influenza A and B (Table 2).
Although vaccination was more common in SARI 
patients, the same factors affected the propensity to 
be vaccinated in persons with ILI or SARI. The adjusted 
odds ratios for the association of various patient char-
acteristics with the likelihood of vaccination showed 
that older age groups and those with chronic diseases 
were most likely to be vaccinated (Table 3). In contrast, 
there was no statistically significant difference in the 
likelihood of vaccination by ethnicity, sex, deprivation 
score, pregnancy, obesity, self-rated health, smoking, 
assisted living or the timing of the admission relative 
to the influenza season (Table 3).
Vaccine effectiveness
The VE against all circulating influenza virus strains, 
adjusted only for the number of weeks from the peak of 
the influenza season, was 32% (95% confidence inter-
val (CI): 7 to 50) for influenza-confirmed SARI and 56% 
(95% CI: 37 to 70) for influenza-confirmed ILI (Table 
4). After also adjusting for the propensity to be vacci-
nated, the estimated VE was 52% (95% CI: 32 to 66) for 
SARI and 56% (95% CI: 34 to 70) for ILI. Thus, adjusting 
for the propensity to be vaccinated had more effect on 
the VE estimate for SARI than for ILI. For ILI, the crude 
and adjusted VE point estimates were the same.
There was no significant change to these estimates 
when excluding patients with missing values (for SARI, 
unadjusted VE was 29% (95% CI: 3 to 48) and adjusted 
VE 50% (95% CI: 29 to 66); for ILI, unadjusted VE was 
56% (95% CI: 37 to 70) and adjusted VE 56% (95% CI: 
34 to 70)). When a logistic regression model was con-
structed and directly adjusted for all the covariates in 
Table 1, the VE was 54% (95% CI: 33 to 69) for SARI 
admissions and 58% (95% CI: 37 to 72) for ILI patients. 
Adjusting for only the variables that were significant 
in the model (p<0.05) resulted in a VE estimate of 54% 
(95% CI: 33 to 69) for SARI and 59% (95% CI: 41 to 72) 
for ILI. When restricting the analysis to within four 
days of onset of symptoms, the adjusted VE for ILI was 
Table 2
Vaccinated and unvaccinated influenza cases by virus type and subtype in hospitalised and community study participants, 
New Zealand, 2013 influenza season*
Influenza virus
type
Hospitalised with 
severe acute respiratory infection 
General practice visit for 
influenza-like illness
Number vaccinated (%) Number unvaccinated (%) Number vaccinated (%) Number unvaccinated (%)
All 82 (100) 142 (100) 44 (100) 438 (100)
A(H1N1) 5 (6) 8 (6) 3 (7) 27 (6)
A(H3N2) 51 (62) 68 (48) 20 (45) 196 (45)
All Aa 68 (83) 95 (67) 28 (64) 262 (60)
All B 14 (17) 48 (34) 16 (36) 180 (41)
ILI: influenza-like illness; SARI: severe acute respiratory infection. 
a One SARI case and four ILI cases tested positive for both influenza A and B viruses. Not all cases of influenza A were subtyped. The number 
of subtypes does not add up to the number of all influenza A viruses identified.
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48% (95% CI: 3 to 68) and for SARI 57% (95% CI: 36 to 
71). When analysed by restricting to a shorter period 
around the peak (weeks 28–40), the VE for ILI was 46% 
(95% CI: 16 to 65) and for SARI 53% (95% CI: 27 to 50). 
For both SARI and ILI influenza-positive cases, the vac-
cination rate was constant over time.
The vaccine was significantly protective among 
patients aged 18–64 years. Specifically, VE was 61% 
(95% CI: 34 to 77) against SARI and 55% (95% CI: 24 
to 73) against ILI. Although with wider CIs, the vaccine 
was also signficantly protective for those aged 0–17 
years, with an estimated VE of 78% for SARI (95% CI: 2 
to 95) and 56% for ILI (95% CI: 6 to 79). For those aged 
65 years and older, VE point estimates were lower for 
SARI at 34%, although CIs crossed zero (95% CI: −28 
to 66), and higher for ILI at 76% although with wide CIs 
(95% CI: 15 to 93) (Table 4).
For SARI patients, VE against influenza A was 39% 
(95% CI: 10 to 58) and against influenza B was 76% 
(95% CI: 54 to 87). For ILI patients, VE against influenza 
A was 58% (95% CI: 32 to 74) and against influenza B 
54% (95% CI: 19 to 75) (Table 4).
The influenza viruses isolated from all of New Zealand 
during February to September 2013 were forwarded 
to the WHO Collaborating Centre for Research and 
Surveillance of Influenza in Melbourne, Australia, for 
further antigenic characterisation. Most of the New 
Zealand influenza A(H1N1) viruses reacted well with 
ferret antisera raised against A/California/7/2009 
virus. Almost all of the A(H3N2) viruses reacted well 
with ferret antisera raised against cell-propagated 
A/Victoria/361/2011 or A/Texas/50/2012 viruses. B/
Yamagata lineage viruses were the predominant B 
viruses in New Zealand in 2013. Although this lineage 
was included in the 2013 southern hemisphere vac-
cine formulation, antigenic drift was observed in these 
viruses, as they reacted better with ferret sera raised 
against B/Massachusetts/2/2012-like virus (selected 
for the southern hemisphere 2014 vaccine) than B/
Wisconsin/1/2010 virus (included in the southern hemi-
sphere 2013 vaccine).
Table 3
Characteristics of non-influenza virus-positive study patients with severe acute respiratory infection and influenza-like 
illness (controls) and their association with influenza vaccination status, New Zealand, 2013 influenza season
Characteristic
Hospitalised with 
severe acute respiratory infection
General practice visit for influenza-
like illness
OR (95% CI) P value OR (95% CI) P value
Age group
6 months–5 years 0.15 (0.08 to 0.27) <0.01 0.14 (0.07 to 0.25) <0.01
6–17 years 0.26 (0.11 to 0.63) <0.01 0.19 (0.11 to 0.34) <0.01
18–45 years 0.42 (0.25 to 0.70) <0.01 0.31 (0.20 to 0.50) <0.01
65–79 years 2.28 (1.30 to 4.00) <0.01 7.9 (3.35 to 18.64) <0.01
≥80 years 2.81 (1.38 to 5.73) <0.01 8.87 (1.01 to 77.66) 0.05
Ethnicity
Māori 0.72 (0.44 to 1.17) 0.19 0.60 (0.25 to 1.47) 0.26
Pacific 0.94 (0.59 to 1.49) 0.79 0.68 (0.38 to 1.22) 0.19
Additional characteristics
Male 1.02 (0.71 to 1.45) 0.92 0.64 (0.43 to 0.96) 0.03
Mean New Zealand deprivation scorea 0.98 (0.91 to 1.05) 0.53 0.98 (0.91 to 1.06) 0.61
Pregnant 1.28 (0.19 to 8.50) 0.80 Not collected –
Current smoker 0.92 (0.54 to 1.56) 0.74 0.57 (0.26 to 1.26) 0.16
Chronic disease 2.65 (1.64 to 4.26) <0.01 2.07 (1.38 to 3.09) <0.01
Obeseb 1.18 (0.73 to 1.92) 0.50 1.08 (0.45 to 2.56) 0.87
Self-defined well-being health status of poor or fairc 1.03 (0.62 to 1.71) 0.92 Not collected –
Frailtyd 3.25 (0.96 to 11.07) 0.06 Not collected –
Dependencee 1.25 (0.55 to 2.83) 0.6 Not collected –
Early in influenza seasonf Not applicable – 1.07 (0.68 to 1.67) 0.78
OR: adjusted odds ratio compared with referent group: female, aged 46–64 years, non-Māori, non-Pacific ethnicity, not in the New Zealand 
deprivation measure of the three lowest deciles (8,9 or 10), not pregnant, current  non-smoker, without chronic disease, not obese, with 
self-rated health average or better, not on long-term oxygen use, living without assistance and admitted to hospital for severe acute 
respiratory infection during the peak influenza season.
a  A meshblock measure reflecting eight dimensions of deprivation distributed into deciles.
b  Subjective assessment of obesity by the clinician.
c  A self-defined, standardised functional well-being health status score.
d  Defined as currently on long-term oxygen use.
e  Requirement for assistance with normal activity or full dependency on nursing care, as reported by the patient or caregiver.
f  Admission or presentation before 1 June 2013.
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Discussion
The 2013 New Zealand influenza season was character-
ised by low incidence and a late peak, with influenza 
A(H3N2) and influenza B most commonly detected. The 
circulating influenza A subtypes were antigenically sim-
ilar to the H1 and H3 components of the 2013 vaccine, 
while the predominant circulating B viruses were line-
age matched, although antigenic drift was observed.
This is the first study comparing VE against medically 
attended ILI and hospitalised SARI due to laboratory-
confirmed influenza from the same population in the 
same season in New Zealand. The ILI surveillance sea-
son started and finished two weeks earlier than SARI 
surveillance. This may reflect a delay between onset of 
cases in the community and their referral to hospital.
After adjustment for the propensity to be vaccinated, 
we found moderate VE, around 50%, against both ILI 
and SARI, suggesting there was unlikely to be a sub-
stantial difference in VE by severity of influenza ill-
ness. However, the study was not powered to test for 
this difference. In addition, the patient groups differed 
by a number of important factors including age and 
ethnicity. The propensity score among patients with 
SARI varied much more than among those with ILI, due 
to the increased likelihood of vaccination among SARI 
patients and more available data on covariates. In par-
ticular, influenza was more often detected in the older 
age groups in the SARI patients and the adjustment 
for the propensity score therefore had a bigger effect 
for SARI patients. There was no significant change to 
VE estimates when the analysis was restricted to four 
days post onset of symptoms, rather than seven days.
The vaccine showed significant effectiveness against 
influenza A for ILI and SARI patients, with protection 
estimated to be lower for SARI patients. On the other 
hand, protection against influenza B appeared higher 
for the SARI patients, but the CIs overlapped for all 
comparisons. The vaccine prevented about 55–60% 
of ILI presentations and SARI hospitalisations in the 
18–64-year age group. In the younger age group, the 
vaccine appeared to be more effective against SARI 
presentations compared with ILI, but the CIs were 
wide. The sample size was too small to make definitive 
VE estimates for the older age group.
Our point estimate for VE against medically attended 
influenza-confirmed ILI was very similar to northern 
hemisphere estimates for the 2012/13 influenza sea-
son, with interim adjusted estimates of 56% (95% CI: 
47 to 63) from the United States [17], a United Kingdom 
mid-season estimate of 51% (95% CI: 27 to 68) [18] and 
a Canadian estimate of 50% (95% CI: 33 to 63) [19]. 
Similarly, VE results for ILI in the 2012/13 season from 
seven study sites in Europe reported  the same virus 
circulation and adjusted estimates for the three circu-
lating strains of 49% (95% CI: 32.4 to 62) for influenza 
B, 50% (95% CI: 28.4 to 65.6) for A (H1N1) and 42% 
(95% CI: 14.9 to 60.7) for A(H3N2) [20].
While we collected information on most suspected 
potential confounding variables, we could not con-
trol for residual confounders. In future years, we will 
collect data on previous presentations with respira-
tory illnesses and previous vaccination. New Zealand 
has added influenza vaccination to its national 
Table 4
Estimated influenza vaccine effectiveness, by participant age group and by influenza virus type and subtype: crude and 
propensity adjusted models, New Zealand, 2013 influenza season
Influenza virus and age group
Hospitalised with
severe acute respiratory infection
General practice visit for
influenza-like illness
Crude modela Propensity adjusted modela Crude model
a Propensity adjusted 
modela
VE (95% CI) VE (95% CI) VE (95% CI) VE (95% CI)
Influenza virus type or subtype
Overall 32 (7 to 50) 52 (32 to 66) 56 (37 to 70) 56 (34 to 70)
A(H1N1) 25 (−132 to 76) 48 (−74 to 85) 50 (−68 to 85) 49 (−90 to 86)
A(H3N2) 11 (−33 to 40) 34 (−2 to 57) 56 (27 to 74) 61 (32 to 77)
All A 15 (−21 to 40) 39 (10 to 58) 55 (29 to 71) 58 (32 to 74)
All B 65 (36 to 81) 76 (54 to 87) 60 (32 to 77) 54 (19 to 75)
Age group
6 months–17 years 72 (−22 to 93) 78 (2 to 95) 56 (6 to 79) 56 (6 to 79)
18–64 years 66 (43 to −79) 61 (34 to 77) 59 (32 to 75) 55 (24 to 73)
≥65 years 35 (−25 to 66) 34 (−28 to 66) 74 (12 to 92) 76 (15 to 93)
VE: vaccine effectiveness, as a percentage.
a All models were adjusted for the number of weeks from the influenza peak.
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immunisation register from 2014. This will provide 
more accurate vaccination history for SARI cases than 
patient self-report.
In conclusion, this study shows a moderate protective 
effectiveness of influenza vaccine against medically-
attended and hospitalised influenza, generally sup-
porting the current national immunisation strategy 
in New Zealand. Pooled data from future years of the 
SHIVERS study will allow more precise VE estimates for 
high-risk subgroups and will also allow more extensive 
comparisons between VE estimates in primary care 
(general practice) and hospital settings.
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